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Local inflammation within the tumor microenvironment is implicated in the 
systemic effects of disease progression, such as immune suppression and metastasis. 
Soluble factors (SF) produced within the tumor, including cytokines, exosomes, 
proteases, and microvesicles, mediate pathological signaling and have emerged as 
putative therapeutic targets. However, SF bioavailability in distributed tissues and the 
impact of disease progression on their dissemination profiles and exposure to various 
immune cell subsets is poorly defined. This stymies progress towards therapeutic 
amelioration of SF signaling activities to improve disease outcomes and is the critical 
knowledge gap this thesis seeks to fill. The central hypothesis is that tumor vascular 
remodeling redirects the organism-wide exposure of SF secreted locally within the tumor 
microenvironment, which may negatively contribute to disease burden by altering the 
bioavailability of molecules important to systemic disease progression. In this thesis, the 
effects of local tissue remodeling in melanoma leading to pathological SF accumulation 
profiles within distributed tissues are elucidated in order to provide insight into the 
potential for localized disease to exert systemic effects and inform opportunities to 
develop better preventive and curative treatment options for advanced melanomas. 
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CHAPTER 1. INTRODUCTION 
1.1 Motivation 
Melanoma remains a significant clinical problem with an estimated 10,000 deaths 
in the US population in 2016 alone (American Cancer Society). While the 5 year survival 
rate for localized melanoma of the skin is around 98%, it drops to 18% when distant 
metastasis is involved (National Cancer Institute). Therapeutic interventions that 
effectively treat advanced melanomas to improve patient outcomes are thus in crucial 
need of development.  
Local immune suppression is known to occur within the pre-metastatic niche prior 
to dissemination [1, 2]. How this immune suppression arises, however, remains unclear. 
The formation of a pre-metastatic niche via cues which promote tumor immune 
suppression, tumor cell survival and outgrowth, as well as pre-conditioning of local 
stromal and bone marrow-derived progenitor cells before metastatic cell dissemination is 
a crucial phase in cancer metastasis [3-5]. Factors secreted within the tumor 
microenvironment are known to play multifaceted roles in facilitating disease 
progression, including immune suppression and dissemination [3]. The pro-metastatic 
secretome is also capable of inducing enhanced vascular permeability and remodeling in 
disseminated tissues [6], activation of tissue-resident fibroblasts and macrophages 
resulting in changes in extracellular matrix (ECM) composition and physical properties 
[7, 8], and recruitment of immune cells which contribute to a pro-tumorigenic, 
inflammatory microenvironment [5, 9, 10] indicating a robust involvement of multiple 
extratumoral signaling pathways in cancer progression. However, the bioavailability of 
tumor-secreted soluble factors (TSF), including various proteins, proteases, exosomes, 
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and microvesicles, and the impact of tumor progression on their capacities to signal in 
disseminated tissues, such as pre-metastatic niches, are poorly defined. This stymies 
progress towards therapeutic amelioration of TSF signaling activities to improve disease 
outcome and is the critical knowledge gap this dissertation seeks to fill.     
 Mechanisms of TSF clearance from the tumor microenvironment and 
dissemination profiles to regional versus systemic tissues likely play major roles in the 
regulation of TSF signaling locality and resulting functions in cancer progression. The 
importance of both extent of TSF dissemination and lymphatic versus blood clearance 
routes are evident in the differences between lymph node versus systemic tissue filtering 
capacities, relative dilutional effects, and selectivity of exposure to tissue-resident cellular 
subsets [11]. However, vascular remodeling due to hyper-angiogenic signaling in primary 
tumors results in haphazard tissue remodeling and a tortuous, dilated, and leaky tumor 
blood vascular network [12, 13] that is accompanied by lymphatic hyperplasia [14]. 
These characteristics are well recognized to manifest in the enhanced permeability and 
retention (EPR) effect in which systemically circulating particulates at the nano- and 
microscales accumulate to a greater extent within malignant relative to healthy tissues 
[15], yet the impact of this vascular remodeling on the clearance and biodistribution of 
TSF remains to be determined.  
In addition to remodeling within the tumor microenvironment, tumor-induced 
remodeling of the structural and cellular organization within tumor-draining tissues has 
the potential to modulate TSF exposure in these sites of disease progression. Tumor 
draining lymph nodes (dLN) are secondary lymphoid tissues important in the adaptive 
immune response and exhibit specialized substructural distributions of cells with distinct 
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immunological functions for antigen presentation and lymphocyte activation. Several 
studies have characterized the partitioning of species by molecular weight within healthy 
and virus infected dLN [16, 17]. However, the effects of tumor dLN remodeling on 
cellular frequencies and distributions as well as extracellular matrix reorganization in 
response to tumor drainage [18-20]  influencing  TSF exposure profiles is unknown. 
Additionally, while the presence of tumor-derived biomolecules within patients’ sera has 
been observed useful for biomarker tests, this also indicates the bioavailability of TSF to 
mediate systemic signaling in disseminated tissues and potential immune-privileged sites 
involved in cancer progression [11]. Tumor-derived pro-angiogenic factor signaling in 
pre-metastatic systemic tissues [21] may further enhance TSF accumulation and exposure 
profiles [3]. Together, these examples highlight the need to elucidate the effects of tumor-
initiated extratumoral remodeling processes that may dynamically influence cellular 
exposure to TSF.   
Ultimately, the long term goal of this work is to characterize the effects of tumor 
growth and remodeling on TSF tissue and cellular exposure profiles to determine the 
extent and localization of tumor-derived factors in malignant disease progression that 
may be targeted and identify opportunities for developing effective treatment strategies. 
The overall objective of this proposal is to provide fundamental insight regarding how 
vascular remodeling in the malignant skin affects the rate, extent, and size-dependence of 
molecular transport and association with local dLN-resident subpopulations versus 
systemic tissue immune cells. The central hypothesis is that vascular remodeling within 
diseased tissues redirects the organism-wide transport of locally secreted TSF and may 
negatively contribute to disease burden by altering the bioavailability of molecules 
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important to cancer progression. This central hypothesis will be tested in rigorous 
preclinical melanoma animal models in the following specific aims. 
1.2 Specific Aims 
Specific Aim 1A: Evaluate the Effects of Tumor Progression on Soluble Factor 
Accumulation, Clearance, and Biodistribution in Melanoma. The working hypothesis 
of this aim is that cancer disease progression alters the bioavailability of TSF within the 
primary tumor, dLN, and systemic tissues. To better understand the effect of disease 
progression on the biodistribution of TSF, a fluorescently-conjugated tracer panel was 
size-matched to relevant TSF 5-500 nm in hydrodynamic diameter and infused into the 
naïve dermis or directly into the dermal lesions of melanoma bearing mice. The extent of 
intratumoral clearance as well as biodistribution into local versus systemic tissues was 
determined by tissue-, tracer size-, and time-resolved analyses. Perfusion of a vascular 
contrast agent followed by micro-computed tomography (µCT) analysis of vascular 
volume, surface area, and mean vessel diameter provided quantitative insight into the 
effect of disease progression on tumor vascular remodeling. Tracer dissemination profiles 
were compared with µCT results to evaluate the extent and time course for which dermal 
vascular remodeling influences molecular clearance and biodistribution. Results 
illustrated that despite tumor progression-induced reductions in TSF drainage to sentinel 
lymph nodes, size-based principles of lymphatic drug delivery are conserved, and that 
tumors exhibit enhanced molecular clearance into circulation, resulting in systemic tissue 
accumulation of TSF. The outcomes of this aim inform the rational design of sentinel 
lymph node-targeted drug delivery strategies as well as future studies implicating that 
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angioplastic therapy might be used to mitigate the pathological effects of altered TSF 
exposure profiles in cancer progression. These results are presented in Chapter 3. 
 
Specific Aim 1B: Determine the Combined Effects of Size and Form on Dermal 
Retention and dLN Accumulation. The working hypothesis of this aim was to inform 
how drug carriers comprised of engineered biomaterials can be leveraged to improve 
treatment efficacy by enhancing the selective accumulation or retention of payload in the 
skin and its dLN. This was accomplished by analyzing the influence of rigid particle 
versus flexible macromolecule hydrodynamic size on profiles of retention in the site of 
dermal injection as well as the corresponding extent of accumulation in dLN and 
systemic off-target tissues. Using a panel of fluorescently labeled tracers comprised of 
inert polymers that are resistant to hydrolysis and proteolytic degradation and spanning a 
size range of widely used drug carrier systems, I determined that macromolecule but not 
rigid particle retention within the skin was size-dependent, whereas the relative dermal 
enrichment compared to systemic tissues increased with size for both tracer types. 
Additionally, these results suggest that intra- versus extracellular availability of delivered 
payload within dLN may be influenced by both the size and form of engineered drug 
carriers. The outcomes of this aim inform how biomaterial-based drug carriers can be 
designed to enhance the selective exposure of formulated drug in target tissues to 
improve the therapeutic efficacy as well as minimize off-target effects of locoregional 
immunotherapy. The results are presented in Chapter 4. 
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Specific Aim 2A: Elucidate the Effects of VEGF-A and -C Endogenous and Induced 
Signaling on Altered Tumor-derived Molecular Biodistribution Profiles. The working 
hypothesis for this aim is that tumor angiogenic and/or lymphangiogenic signaling 
mechanisms underlie the altered clearance and biodistribution of TSF observed with 
disease progression characterized in Aim 1A. Therefore, the effects of endogenous and 
induced or suppressed angiogenic and lymphangiogenic signaling during melanoma 
progression on TSF molecular biodistribution from tumors was determined by 
intratumorally infusing a tracer panel in melanoma bearing mice divided into cohorts 
treated with an angiogenic signaling inhibitor or with tumors overexpressing the 
lymphangiogenic soluble ligand, vascular endothelial growth factor (VEGF)-C. 
Separately, perfusion of vascular contrast agent followed by µCT analysis and 
immunohistochemistry (IHC) staining for blood and lymphatic vessels were used to 
determine the extent of vascular normalization due to applied inhibition and 
overexpression conditions. The results of this aim reveal that clearance from tumors is 
increased with VEGF-C overexpression and VEGFR-2 inhibition. VEGFR-2 inhibition 
partially recovers 500 and 10 nm tracer dLN accumulation, while VEGF-C 
overexpression results in reduced systemic tissue exposure to 500 and 30 nm tracers. The 
outcomes of this aim inform how TSF transport profiles may be modulated with 
angioplastic therapies that can be used to mitigate the detrimental effects of endogenous 
molecules from the tumor microenvironment or improve tumor-administered therapy 
bioavailability in locoregional tissues. These results are presented in Chapter 5. 
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Specific Aim 2B: Delineate the Influence of Melanoma on Size-dependent Molecular 
Distribution to Immune Cells within dLN versus Systemic Tissues. The working 
hypothesis for this aim is that increased tumor vascular permeability as well as 
diminished lymphatic function will alter the capacity of TSF active in the regulation of 
immune signaling to distribute amongst subpopulations of systemic tissue-resident 
immune cells versus dLN-resident cells that exhibit distinct substructural distributions as 
well as immunological functions. Herein, the effects of tumor vascular remodeling, 
including those resulting from tumor VEGF-C overexpression (OE) and VEGF receptor-
2 inhibition, on exposure of sentinel lymph node-resident as well as systemic tissue-
resident phagocytic and immune cell subpopulations to factors derived from the tumor 
microenvironment were determined. The in vivo biodistribution and uptake by immune 
cell subtypes of a panel of fluorescently labeled macromolecular and particulate tracers 
size-matched to physiological biomolecules ranging from 10-500 nm in hydrodynamic 
diameter after intradermal or intratumoral infusion in C57Bl6 mice was resolved in a 
temporal- and tissue-resolved fashion by flow cytometry. The changes in dLN 
paracortex-resident and barrier cell frequencies and distributions were also determined by 
IHC of frozen dLN sections. The results of this aim indicate a reduced percentage of 30 
and 10 nm tracers associated with LN-resident barrier cell macrophages and dendritic 
cells, but similar uptake levels by B and T cell populations in tumor dLN versus naïve 
tissues. The outcomes of this aim inform that tissue-level changes in transport to and 
molecular abundance within the dLN do not translate to equally proportional changes in 




1.3 Significance  
This work provides valuable insight into the following: 1) the role of vascular 
remodeling altering TSF clearance and biodistribution profiles, 2) the conservation of 
size-dependent drug delivery principles for dLN targeted therapy in advanced melanoma, 
3) the differences between particulate and macromolecular size-dependent transport 
profiles for locoregional immunotherapy, and 4) the relative distribution of TSF among 
dLN-resident subpopulations versus systemic tissue immune cells. This study 
investigated how tumor progression and interventions in angiogenic and 
lymphangiogenic signaling alters molecular transport by using relevant mouse models of 
melanoma and highly quantitative tissue- and cellular-level analysis techniques. These 
results inform of potential local and systemic TSF transport activities that may be 
targeted as well as how angiogenic or lymphangiogenic therapies may affect aberrant 
molecular biodistribution profiles. Furthermore, the role of vascular changes in 
pathological molecular transport and signaling could become an important aspect for 
evaluation in other chronic inflammatory diseases or in wound healing applications. The 
incorporation of a range of sizes of particulate and macromolecular forms in these studies 
allows the results to apply not only to endogenous tumor-secreted biomolecules, but also 
to bioengineered drug carriers and informs design criteria based upon desired transport 
profiles and selective exposure to immune cell subsets in the dLN that will prove useful 
in vaccine and locoregional immunotherapy applications. 
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CHAPTER 2. BACKGROUND AND LITERATURE REVIEW  
2.1 Tumor Progression and Advanced Disease Outcomes 
 The transition of cancer from a locally confined to a widespread disease with 
disseminated effects, such as metastasis and anti-tumor immune suppression, not only 
makes treatment by resection or conventional methods difficult, but results in greatly 
increased rates of morbidity. Cancer is accompanied by many hallmarks within the tumor 
microenvironment that enable disease progression at the local level, such as enhanced 
proliferation, replicative immortality, increased survival signaling of cancer cells, and 
tumor vascular remodeling [22]. However, late stage cancers present with advanced 
hallmarks including anti-tumor immune suppression and metastasis to regional lymph 
nodes as well as distant tissues that result in poor disease outcomes.  
 
Figure 2.1 Survival Statistics for Melanoma of the Skin by Stage at Time of 
Diagnosis. (National Cancer Institute, SEER 18 2006-2012) 
 Specifically, melanoma remains a significant clinical problem with an estimated 
10,000 deaths in the US population in 2016 alone (American Cancer Society). While the 
5 year survival rate for localized melanoma of the skin in 2000 for both sexes was 98.4%, 
it drops to an unfortunate 17.9% when distant metastasis is involved (Figure 2.1). 
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Moreover, the main sites of melanoma metastasis—bone, brain, liver, and lung, are 
within tissues that make detection and treatment challenging. Additionally, mechanisms 
initiated by cancer cells have been shown to result in enabling tumor progression through 
evasion of immune destruction and promoting anti-tumor immune suppression [23]. 
Together these data rationalize further exploring the underlying signaling of advanced 
cancer associated pathologies to develop better preventative and remedial treatment 
options. 
2.2 Tumor-secreted Soluble Factors 
2.2.1 Soluble Factor Signaling within the Tumor Microenvironment 
SF (soluble factors) produced within the tumor microenvironment play important 
and multifaceted roles in the regulation of malignant disease progression. TSF such as 
cytokines, chemokines, proteases, and microparticles (including microvesicles and 
exosomes) mediate intercellular signaling at the cell- and tissue-levels to regulate cellular 
proliferation [24], angiogenesis [25] and lymphangiogenesis [20], recruitment of 
regulatory immune cells [26, 27], as well as extracellular matrix remodeling [28] via their 
direct effects or nucleic acid and/or protein transfer (Figure 2.2). Accordingly, numerous 
TSF and their associated signaling pathways active within the primary tumor have 
emerged as potential therapeutic targets given their implicated role in the promotion of 
malignant disease progression associated with poor prognosis including metastasis and 
anti-tumor immune suppression. However, the bioavailability and potential for TSF to 
mediate extratumoral signaling processes are relatively understudied which hinders the 
development of effective treatments against systemic disease progression. 
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Figure 2.2 Categories of Endogenous TSF and Their Potential Signaling Outcomes. 
 
2.2.2 Alterations in Soluble Factor Quality and Quantity with Disease Progression 
 A multitude of either tumor or stromal cell-secreted biomarkers exhibit altered 
levels of expression in the tumor microenvironment, which make them useful prognostic 
markers [29-31], and implicate their signaling pathways in disease progression. Tumor 
growth and the unchecked proliferation of cancer cells accumulating genetic mutations 
drive the upregulation and diversity of TSF [32, 33]. For example, metallothionein 
(cysteine-rich proteins with molecular weights of 500-14,000 Da) overexpression 
observed in IHC analysis of tumor sections, which also correlated with CD68+ 
macrophage infiltration, has been linked to tumor progression and increased risk of 
metastasis in cutaneous malignant melanoma [29].  Other overexpressed melanoma-
derived SF include matrix metalloproteinase-2[34] (a 72,000 Da type IV collagenase), 
transforming growth factor-β [35] (a 25,000 Da autocrine growth factor), and 
indoleamine 2,3-dioxygenase[30] (a 45,000 Da heme-containing enzyme). In addition to 
proteins, mRNA, miRNA, DNA, and other genetic materials are packaged and secreted 
from cells in vesicular bodies termed exosomes (~20-100 nm in diameter) and 
microvesicles (100-1000 nm in diameter) [36]. These vesicles provide a high 
 12 
concentration of signaling molecules that has been shown to play roles in cancer 
progression such as through influencing metastasis [37] and immunosuppression [38]. 
The range in TSF sizes and forms indicate the need for further studying how the physical 
and functional properties of these tumor-derived signaling factors influence systemic 
disease progression.  
 TSF are specifically involved in melanoma progression through promotion of 
invasion [39], metastasis [40], cytokine secretion [41], and anti-tumor immune 
suppression [41]. For example, melanoma inhibitory activity (MIA) is a soluble protein 
derived from macrophages that was observed to enhance the further production of MIA 
by melanoma cells and increase their invasive behavior in vitro [39]. In another study, a 
soluble form of VEGFR-1 was identified to play a role in modulating the invasiveness of 
melanoma cells and their metastatic loci [40]. Soluble program death-ligand 1 (sPD-L1) 
has also recently been implicated in melanoma as higher levels in the blood were 
associated with increased levels of pro-inflammatory cytokines and an 
immunosuppressive phenotype with decreased overall survival [41]. These examples 
indicate specific TSF signaling pathways that are relevant in melanoma, which is 
considered herein, but TSF profiles may differ for other forms of cancer. 
2.3 Implications of TSF in the Systemic Effects of Cancer 
2.3.1 Evidence of Tumor Soluble Factor Bioavailability in Circulation 
 Molecules secreted within the tumor microenvironment that may be found in 
blood circulation have become useful as serological biomarkers [42-45], but also provide 
evidence for the bioavailability and potential signaling of TSF in systemic tissues as a 
possible mechanism of disease progression in multiple forms of cancer. These markers, 
identified from blood samples, rather than tumor biopsy which aids in clinical evaluation 
and treatment of many cancers include S100B and lactate dehydrogenase (LDH) in 
advanced melanoma[42], prostate-specific antigen (PSA) levels in prostate cancer[43], 
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and heat shock protein 90A (HSP90A) for early breast cancer detection[44], amongst a 
multitude of others. Vesicular forms of soluble factors may also be present in the serum 
of cancer patients, such as increased concentrations of exosomal miR-373 in women with 
estrogen- and progesterone-negative breast cancers[45]. Interestingly, many studies of 
vesicle-borne signaling in mediating cancer progression implicate extratumoral functions 
[37, 38] indicating the need for further studying the clearance and biodistribution of these 
tumor-derived signaling particulates to determine how TSF macromolecular versus 
vesicular form impacts tissue- and cellular-level exposure profiles.   
2.3.2 Tumor-derived Soluble Factors Implicated in Metastasis, Immunosuppression, 
and Cancer-associated Thrombosis 
 In addition to SF function within the tumor microenvironment, tumor-derived SF 
have been reported to be active in signaling within distant tissues, such as the lymph 
nodes, liver, lungs, kidneys, and spleen. For example, intravenous (i.v.) infusion of 
melanoma-derived exosomes promotes metastasis by directing host progenitor cell 
differentiation toward a pro-metastatic phenotype [46]. Treatment with mammary tumor-
conditioned media can also induce lung and lymph node remodeling to accelerate 
spontaneous metastasis [47]. Moreover, tumor antigen presentation in tumor-draining 
lymph nodes (TDLN) is implicated in directing anti-tumor immune suppression [20, 48]. 
These data therefore suggest mechanisms of signaling to distributed tissues that direct the 
activity of SF in facilitating disease progression that are not restricted to the primary 
tumor. 
 Mechanisms of SF clearance from the tumor microenvironment and distribution 
to disseminated tissues are anticipated to play important roles in the regulation of SF 
signaling locality and of resulting function in cancer. This has been widely considered in 
the context of tumor lymphatic transport function, in particular for its role in facilitating 
cellular invasion and metastasis [49-51] and as a conduit for immune modulatory SF to 
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reshape the TDLN immune microenvironment [20, 52]. The role of SF clearance via the 
blood vasculature and resulting distribution in systemic tissues on the other hand has 
been largely overlooked. However, treatment with melanoma-conditioned media redirects 
Lewis lung carcinoma metastasis from the lung to the kidney, spleen, intestine, and 
oviduct [5], tissues more typical of melanoma dissemination, suggesting a potential role 
for systemically circulating tumor-derived SF in directing organism-wide responses to 
growing tumors. Interestingly, TDLN-targeted, but not systemically infused, toll-like 
receptor ligand adjuvant therapy has been shown to be efficacious in reducing tumor 
burden [48] by exploiting localized depots of endogenously produced tumor antigen 
within TDLN delivered via tumor-draining lymphatics. As cancer-associated thrombosis 
is also a significant cause of patient morbidity in cancer, tumor-derived microparticles 
expressing tissue factor have been demonstrated to exhibit procoagulant activity and are 
associated with acute thrombocytopenia when injected into mice [53]. Thus, the relative 
contribution of blood versus lymphatic-mediated SF clearance and resulting 
accumulation in associated tissues may not only influence SF signaling activity and role 
in disease progression but also susceptibility to therapeutic interventions neutralizing or 
exploiting SF function. Furthermore, the vast majority of cancer-related deaths are due 
not to the local effects of the primary tumor, but rather the systemic effects of cancer 
such as metastasis [54]. Thus, there is a clear need to develop understanding of the 
mechanism of SF dissemination to and bioavailability within systemic tissues. 
2.3.3 Systemic Tissues Adversely Impacted by Melanoma Progression 
 Most cancers, including melanoma, exhibit organ-specific pre-metastatic niche 
formation which implicates TSF pre-conditioning as a directed process in specific tissue 
sites. Major tissues afflicted by melanoma metastasis include lung, brain, bone, liver, 
dLN, and other areas of the skin [55]. Melanomas are observed to metastasize primarily 
to regional dLN [55]. Moreover, tumor dLN, but not contralateral non-draining LN, are 
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bathed in TSF by virtue of their proximity to the tumor and lymphatic drainage function 
[20, 48]. Because the dLN and other tissues are organotropic sites of metastasis, it would 
greatly benefit the development of advanced cancer treatments and understanding the role 
of TSF in pre-metastatic niche formation by identifying the extent of TSF exposure 
within these sites over the course of disease progression.  
2.4 Tissue Physical Properties Regulating Soluble Factor Transport Profiles 
2.4.1 Blood and Lymphatic Clearance of Biomolecules from the Interstitium 
 Principles of size exclusion and mass transport along with physical tissue 
properties regulate TSF clearance and biodistribution profiles which determines their 
potential to signal in local versus disseminated tissues. Within the healthy interstitium 
(e.g. the skin) the processes underlying SF dissemination via blood or lymphatic-
mediated clearance are controlled by the physical parameters of the tissue 
microenvironment as well as the size of the SF. Clearance of SF less than 5.4 nm in 
hydrodynamic diameter occurs rapidly via resorption into the venous blood capillaries 
[56], whereas SF 5-100 nm in diameter are too large to be resorbed directly into systemic 
circulation due to the physiological pore size limits for transcapillary transport and are 
cleared instead from the interstitium via interstitial flow and lymphatic transport 
mechanisms [56]. Changes in the biophysical characteristics of the interstitium and 
vasculature may therefore result in altered molecular transport and modify TSF signaling. 
2.4.2 Impact of Interstitial Fluid Pressure on Molecular Transport 
 While diffusion, the process by which the net movement of molecules proceeds 
along a concentration gradient, can facilitate molecular transport over short length-scales, 
another important factor mediating interstitial molecular transport over longer length 
scales is hydrostatic pressure gradients and solvent-solute drag. Capillary filtration and 
fluid reabsorption drives the bulk fluid exchange within the interstitium. The interstitial 
fluid hydrostatic pressure is also maintained by lymphatic vessels constantly draining 
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excess fluid from the interstitium to prevent edema. Solvent-solute drag then mediates 
transport of molecules; however, in cases of altered hydrostatic pressure gradients, 
transport by diffusion may become more dominant [57].  
2.4.3 Extracellular Matrix Effects on Soluble Factor Transport 
 The extracellular matrix constrains the transport of larger SF, such that molecules 
greater than ~100 nm in hydrodynamic diameter must be removed from peripheral tissues 
and transported to dLN by dendritic cell-mediated trafficking mechanisms which 
transpire over a period of several days [58, 59]. While steric and hydrodynamic 
interactions primarily influence the transport of molecules, electrostatic forces may affect 
interstitial diffusion as well when the fiber size is comparable to the Debye length (i.e. 
important for interactions with small glycosaminoglycans, but not larger collagen fibers) 
[60]. Thus, the use of near neutral molecules is desirable to avoid hindered diffusion by 
electrostatic effects in drug delivery [60]. Overall, solvent-solute drag, solute diffusion, 
hemodynamic forces, charge, and colloid osmotic gradients in combination with SF size 
direct the clearance and biodistribution profiles of SF from interstitial tissues [61]. 
2.5 Tumor-induced Microenvironmental Remodeling in Cancer 
2.5.1 Role of VEGF-A and –C Signaling Axes in Vascular Remodeling 
 Local vascular remodeling in diseased states has the potential to dramatically 
influence blood versus lymphatic-mediated clearance and biodistribution of SF by 
altering SF transport mechanisms and barriers. For example, hyper-angiogenic signaling 
via VEGF-A upregulation during tumor formation and growth causes haphazard tissue 
remodeling and spurs a tortuous, dilated, and hyper-permeable [12, 13, 62] tumor blood 
vascular network. VEGF-C overexpression was found to result in lymphatic hyperplasia, 
increased volumetric flow rates of peritumoral lymphatics, and increased metastasis to 
tumor dLN by four-fold [14]. Additionally, increased interstitial fluid pressure [63, 64] 
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has been shown to limit the penetration and efficacy of molecular drug delivery to tumors 
[65-67] as well as the biophysical changes in extracellular matrix properties within some 
tumors including increased collagen density [68, 69]. Tumor vascular remodeling is well 
recognized to manifest in the enhanced permeability and retention effect in which 
systemically circulating particulates at the nano- and microscales accumulate to a greater 
extent within malignant relative to healthy tissues [15].  Yet while changes in the tumor 
vasculature have been studied and exploited for tumor-targeted drug delivery 
applications, the impact of vascular remodeling changes on the clearance and 
biodistribution of endogenous SF from a primary tumor is unknown.  
2.6 Molecular Transport in Lymph Nodes 
2.6.1 Transport and Organization within the Lymph Node 
Lymph nodes function as the body’s major hubs for lymphocyte transport, 
passage through which is intrinsically complex. Cells and lymph-borne solutes from local 
tissues are delivered and incompletely removed via lymphatics acting in a unidirectional 
manner due to one-way valves. Once in the lymph node, cells are subdivided into T and 
B cell zones while fluids and small molecules (<70 kDa) are shuttled within the lymph 
node via fibroblastic reticular cell-lined conduits. High endothelial venules (HEVs) also 
facilitate entry of cells as well as exchange of solutes and fluids with the systemic blood 
circulation (Figure 2.3). [70] 
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Figure 2.3 Lymph Node Transport and Organization. Lymphatic uptake of small 
molecules, particulates, and cells within the tissue interstitium results in carriage to 
dLNs, tissues whose microstructure orchestrates the comingling of lymph and 
lymphocytes to facilitate adaptive immunity and tolerance. The transport role of the 
lymphatics in the delivery of peripheral tissue–derived antigens, cytokines and 
chemokines, immune modulatory particles, and immune cells can thus modulate the 
immunological and biophysical microenvironment of dLNs to influence adaptive 
immune response in multiple ways. 
2.6.2 Lymph Node Substructure and Remodeling with Disease 
The cellular and molecular distribution profiles within lymph nodes are 
significantly influenced by lymphatic transport function. For example, in the absence of 
dermal lymphatics, disorganized stromal cell distributions, minimal B cell follicle 
definition, and smaller or collapsed high endothelial venules [71] are found in skin 
draining but not other lymph node localities (Figure 2.4), consistent with remodeling 
responses induced within dLNs when afferent lymph flow is occluded [72]. These lymph 
node organizational changes correspond with abnormal distributions of CCL21 and 
chemokine (C-X-C motif) ligand (CXCL) 13 [71], chemokines that direct T and B cell 
positioning within the lymph node, respectively, as well as T cell zone fibroblastic 
reticular cells and reticular fibers [71], which regulate T cell migration [73]. Together 
with in vitro observations of T zone fibroblastic reticular cell organization, proliferation, 
and secretion of CCL19 and CCL21 sensitivity to flow [74] suggests that lymphatic 
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transport-regulated intranodal fluid flow may modulate chemokine-dependent 
organizational and structural remodeling within the lymph node interstitium. 
In addition to flow putatively providing organizational cues, lymph-borne solutes 
and cells are implicated in directing lymph node remodeling. For example, vascular 
endothelial growth factor (VEGF) drained from the inflamed skin in a delayed-type 
hypersensitivity skin model induce lymphatic vessel remodeling and expansion within 
dLNs [75]. Additionally, microparticles containing tumor necrosis factor secreted by 
peripheral tissue-resident mast cells and transported via lymphatics induce lymph node 
hypertrophy [76]. Lymph migrating dendritic cells also direct the remodeling of the 
lymph node fibroblastic reticular network after immunogenic challenge [77], while the 
extent of cellular remodeling of the lymph node interstitium has been shown to be 
proportional to the number of mature lymph-transported dendritic cells [78]. Dendritic 
cells also direct the proliferation of endothelial cells and HEV expansion within dLNs 
after either immunization or subcutaneous adoptive transfer of dendritic cells [79]. 
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Figure 2.4 Microstructures of skin dLNs. Normal (left), impaired (middle), and 
tumor (right) lymphatic transport are shown immunohistochemically and 
schematically, emphasizing representative collagen organization, T and B cell 
segmentation, and HEV remodeling responses. Scale bars, 100 µm. Modified from 
references [70, 71, 80-82]. 
Given the importance of microstructural properties and cellular distributions in 
regulating lymph node efficacy at directing adaptive immune response and 
immunological tolerance, a potential pathophysiological role is suggested by the lymph 
node remodeling that accompanies numerous disease states. As one example, sentinel, or 
tumor-draining, lymph nodes are exposed to a high concentration of lymph-transported 
molecules from the tumor interstitium by virtue of their proximity to growing tumors [18, 
48]. Signaling pathways active within the local tumor microenvironment that result in 
tissue remodeling associated with cancer cell survival [83], invasion [84-86], and 
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immune suppression [20] therefore have the potential to be operational within TDLN. We 
recently analyzed lymph nodes from B16 melanoma-bearing mice with respect to tumor 
stage and found that melanoma lymphatic drainage was associated with alterations in 
lymph node hyaluronic acid and collagen content corresponding with physical 
adaptations that manifest in tumors [83, 87, 88] including increased intranodal pressures 
[18, 89, 90] and increased lymph node tissue stiffness and viscoelasticity [18]. These and 
other remodeling responses are important as they have the capability to influence critical 
cellular processes in the lymph node, including cell proliferation, migration, and 
lymphocyte homing.  
2.7 Biomaterial Design for dLN Targeted Immunotherapies and Vaccines 
2.7.1 Physicochemical Carrier Properties Influence Clearance and Dissemination 
Biomaterials-based formulation strategies offer many advantages for maximizing 
the therapeutic potential in target tissues while limiting off-target effects, which are 
controlled by drug clearance rates and profiles of biodistribution. It has been previously 
demonstrated that the size of antigen conjugated polystyrene spheres influenced antibody 
titers, LN cellular uptake, and anti-tumor immune response, although the exact 
mechanisms by which these were accomplished is still undetermined [91]. Similarly, a 
study by Manolova, et al. [92] demonstrated the effect of particle size on cellular 
transport and lymphatic uptake, which included many sizes of polystyrene particles and 
one virus-like particle, but had no direct, size-matched comparison between different 
formulations or flexibilities (the virus-like particle was 30 nm in diameter while the 
adjacent particle sizes were 20 and 100 nm). Additionally, the effect of biomaterial form 
and flexibility has been studied with respect to improving carrier circulation [93] and 
uptake of particles by cells [94], but has not been previously explored as a variable 
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influencing dermal retention or dLN accumulation which are pertinent to locoregional 
immunotherapy and vaccine design. 
2.7.2 Locoregional Immunotherapy and Alternative Applications 
Increasing the efficiency and selectivity of agent delivery or retention in order to 
prolong drug exposure in skin and dLN (Figure 2.522) is desirable in a variety of 
immunotherapeutic regimens. For example, intralymphatic immunotherapy [95, 96] as 
well as intradermal (or intralesional) injection for allergic contact dermatitis and plaque 
psoriasis [97] or oncolytic virus therapy in melanoma [98] would benefit from 
biomaterial strategies providing increased local concentrations, reduced off-target effects, 
and eliminating the need for repeated local injections. While some attempts have been 
made such as with skin-permeating nanogel systems [97], further studies are necessary to 
inform application-specific tailoring of biomaterial-based carriers for local tissue and 
dLN targeting.  
 
Figure 2.5 Locoregional Therapeutic Administration Scheme. Intradermal 
administration and biomaterial carrier system properties result in localized delivery that is 
influenced by balancing retention at the injection site, accumulation in dLN, and off-
target systemic tissue levels. 
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CHAPTER 3. MELANOMA PROGRESSION REDUCES 
MOLECULAR CLEARANCE FROM TUMORS AND 
BIODISTRIBUTION TO DRAINING LYMPH NODES WHILE 
INCREASING SYSTEMIC TISSUE ACCUMULATION [62] 
3.1 Introduction 
 Tumor-secreted soluble factors (TSF) such as cytokines, chemokines, proteases, 
and microparticles (including microvesicles and exosomes) mediate intercellular 
signaling at the cell- and tissue-levels to regulate cellular proliferation [24], angiogenesis 
[25] and lymphangiogenesis [20], recruitment of regulatory immune cells [26, 27], as 
well as extracellular matrix remodeling [28] via their direct effects or nucleic and/or 
protein transfer. Accordingly, numerous TSF and their associated signaling pathways 
activated within the primary tumor have emerged as potential therapeutic targets given 
their implicated role in the promotion of malignant disease progression associated with 
poor prognosis including metastasis and anti-tumor immune suppression. 
 In addition to their function within the tumor microenvironment, TSF have 
reported activities in signaling to distant tissues, such as the lymph nodes, liver, lungs, 
kidneys, and spleen, which exacerbate disease progression. For example, intravenous 
(i.v.) infusion of melanoma-derived exosomes promotes metastasis by directing host 
progenitor cell differentiation toward a pro-metastatic phenotype [46]. Treatment with 
mammary tumor-conditioned media can also induce lung and lymph node remodeling to 
accelerate spontaneous metastasis [47]. Moreover, tumor antigen presentation in TDLN is 
implicated in directing anti-tumor immune suppression [20, 48]. These data therefore 
suggest mechanisms of signaling to distributed tissues that direct the activity of TSF in 
facilitating disease progression that are not restricted to the primary tumor.  
 As such, mechanisms of TSF clearance from the tumor microenvironment and 
distribution to disseminated tissues likely play important roles in the regulation of TSF 
 24 
signaling locality and resulting function in cancer. This has been widely considered in the 
context of tumor lymphatic transport function, in particular for its role in facilitating 
cellular invasion and metastasis [49-51] and as a conduit for immune modulatory TSF to 
reshape the TDLN immune microenvironment [20, 52]. The role of TSF clearance via the 
blood vasculature and resulting distribution in systemic tissues on the other hand has 
been largely overlooked. However, treatment with melanoma-conditioned media redirects 
Lewis lung carcinoma metastasis from the lung to the kidney, spleen, intestine, and 
oviduct [5], tissues more typical of melanoma dissemination, suggesting a potential role 
for systemically circulating TSF in directing organism-wide responses to growing 
tumors. Interestingly, TDLN-targeted, but not systemically infused, toll-like receptor 
ligand adjuvant therapy has been shown to be efficacious in reducing tumor burden [48] 
by exploiting localized depots of endogenously produced tumor antigen within TDLN 
delivered via tumor-draining lymphatics. Thus, the relative contribution of blood versus 
lymphatic-mediated TSF clearance and resulting accumulation in associated tissues may 
not only influence TSF signaling activity and role in disease progression but also 
susceptibility to therapeutic interventions neutralizing or exploiting TSF function. 
 An added level of complexity in this problem is the influence of vascular 
remodeling that occurs within growing tumors. Hyper-angiogenic signaling during tumor 
formation and growth causes haphazard tissue remodeling and a tortuous, dilated, and 
leaky [12, 13] tumor blood vascular network that is accompanied by lymphatic 
hyperplasia [14]. These characteristics are well recognized to manifest in the enhanced 
permeability and retention effect in which systemically circulating particulates at the 
nano- and microscales accumulate to a greater extent within malignant relative to healthy 
tissues [15]. Yet while this is often exploited for tumor-targeted drug delivery 
applications, its impact on the clearance and biodistribution of TSF and therapeutic 
agents administered directly to the tumor remains as-of-yet unknown. 
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 Hence, although TSF and intratumorally administered therapeutic agents have 
been regarded for their role in local signaling within the tumor microenvironment, their 
bioavailability in distributed tissues and the impact of disease course on these 
biodistribution profiles has been overlooked. Unfortunately, detection and quantification 
of endogenously produced TSF are limited by significant dilutional effects as well as 
uncertainty in the spatial and temporal source of constitutive or inducible reporter 
systems. Furthermore, biodistribution analysis of specific exogenously supplied TSF is 
challenging due to degradation in vivo. To circumvent these limitations, we established a 
panel of near-infrared fluorescent tracers comprised of inert polymers that are resistant to 
hydrolysis and proteolytic degradation. Since TSF and therapeutic agents such as small 
molecule drugs and engineered drug delivery vehicles vary widely in hydrodynamic 
diameter and the rate and extent of blood versus lymphatic clearance from healthy tissues 
are acutely size-dependent [56, 58], tracers over a physiological biomolecule size-
matched range of 5-500 nm in hydrodynamic diameter were chosen. We examined in a 
temporal- and tissue-resolved manner the clearance and biodistribution of fluorescent 
tracers after infusion into the B16F10 melanomas of C57Bl6 mice at prescribed tumor 
growth phases or in the skin of naïve animals. Our findings support the hypothesis that 
lymphatic drainage significantly enriches levels of tumor-derived factors in dLN, that 
melanoma progression attenuates lymphatic-mediated transport but not the predominant 
molecular size regime accumulating within TDLN, and that vascular remodeling within 
advanced melanomas increases the access of factors derived from the tumor interstitium 
to systemic tissues. 
3.2 Materials and Methods 
3.2.1 B16F10 Mouse Melanoma Cell Culture 
B16F10 murine melanoma cells were cultured in Dulbecco’s Modified Eagle 
Medium supplemented with 10% heat-inactivated fetal bovine serum and 1% 
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penicillin/streptomycin/amphotericin B. Media, serum, and antibiotics were obtained 
from Life Technologies (Carlsbad, CA). Cell lines were routinely checked and confirmed 
to be negative for mycoplasma infection and rodent pathogens. 
3.2.2 TSF Analysis in Tumor Cell Conditioned Media 
48 hour B16F10 cell-conditioned serum-free medium, concentrated 20x by 
lyophilization after removing any possible cells by centrifugation at 300xg for 5 minutes, 
was fractionated in a size-resolved manner on a Sepharose CL-6B (GE Healthcare, 
Pittsburgh, PA) gravity chromatography column. The protein and deoxyribonucleic acid 
(DNA) content in fractionated media was analyzed using the bicinchoninic acid assay 
(Thermo Fisher Scientific Pierce, Waltham, MA) or by incubation with a 0.5x solution of 
GelRed (Biotium Inc., Hayward, CA) on an orbital shaker followed by absorbance or 
fluorescence measurements (BioTek Instruments Inc, Winooski, VT), respectively.  
3.2.3 Near-infrared Fluorescent Tracers and Conjugation 
500 and 50 nm fluorescent (580/610 nm and 660/680 nm excitation/emission, 
respectively) carboxylate-modified microspheres were purchased from Life 
Technologies. 500 kDa or 10 kDa amine-dextrans (Sigma-Aldrich, St. Louis, MO) were 
covalently labeled by incubation for 4 hours in 0.1 M NaHCO3 buffer at pH 8.4 on a 
shaker with Alexa Fluor 700 NHS-Ester or Alexa Fluor 610-X NHS-Ester dye (Life 
Technologies), respectively. Individual fluorescent dextran conjugates were purified from 
unreacted free dye by Sepharose CL-6B gravity column chromatography. Purified 
dextran-fluorophore conjugates were confirmed to be free of unconjugated dye by 
Sepharose CL-6B gravity column chromatography analysis. The size and zeta potentials 
of 500 and 50 nm fluorescent microspheres as well as 500 and 10 kDa dextran-AF700 
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conjugates suspended in Dulbecco’s Phosphate Buffered Saline (D-PBS, Life 
Technologies) were confirmed using a Zetasizer Nano ZS (Malvern Instruments Ltd, 
WR14 1XZ, United Kingdom). All reagents were used and maintained under sterile 
conditions. 
3.2.4 B16F10 Mouse Melanoma Animal Model 
C57Bl6 mice were purchased from Jackson Laboratories. All protocols were 
approved by the Institutional Animal Care and Use Committee. 0.5x10
6
 B16F10 murine 
melanoma cells were intradermally implanted into the left dorsal skin of 6-8 weeks old 
mice on day 0. Tumors were monitored in anesthetized mice by caliper measurements of 
melanoma width, length, and depth and reported as an ellipsoidal volume. For 
intradermal injections, a depth-marked 27 gauge needle (Becton Dickinson, Franklin 
Lakes, NJ) was inserted perpendicularly into the center of the tumor of mice anesthetized 
with isofluorane and 10 µL of the fluorescent tracer solution (1.2x10
8
 500 nm spheres, 
7.9x10
11
 50 nm spheres, 23.8 µg 500 kDa AF700-dextran, and 3 µg of 10 kDa AF610-
dextran) in saline was co-infused by syringe pump at a rate of ~300 nL per sec for a slow 
infusion rate that resulted in minimal alterations in interstitial pressure. In the results, day 
post B16F10 implant refers to the day on which tracer injections were made. 
Alternatively, naïve mice were injected in the same manner with the same fluorescent 
tracer panel solution in the dermal layer of the left dorsal skin. For i.v. injections, 3 µg of 
10kDa AF610-dextran in 100 µL saline was injected with a 29 gauge insulin syringe into 
the jugular vein of mice. The syringe was aspirated to withdraw a small amount of blood 
before and after injection to confirm that the entire volume was administered i.v.  
3.2.5 Micro-computed Tomographic Imaging and Quantification of Vasculature 
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Animals were perfused with neutral buffered formalin for 10 minutes, a saline 
wash for five more minutes, and MicroFil (Flow Tech Inc., Carver, MA) catalyzed at a 
viscosity appropriate for small vessels (5 mL lead-based contrast agent: 2.5 mL diluent: 
0.25 mL curing agent) by syringe with the application of constant pressure. Afterwards, 
perfused mice were carefully stored at 4°C overnight to cure the contrast agent. The 
following day, skin or tumor samples were harvested and stored in D-PBS. Micro-
computed tomographic imaging was performed using a SCANCO Medical µCT50 
(SCANCO USA, Inc., Wayne, PA, USA). µCT image slices were constrained using 
manual selection of the sample outline and processed with a Gaussian filter at a global 
threshold via the SCANCO Medical µCT Evaluation Program before 3-dimensional 
reconstruction. In-house designed algorithms were used to calculate the vascular volume, 
vascular surface area, and mean vessel diameter within tissue samples [99].  
3.2.6 Tracer Biodistribution Analysis 
At prescribed times post injection (p.i.), the tumor-draining and non-tumor-
draining axillary and brachial lymph nodes, tumor or skin at the injection site, along with 
the spleen, lungs, liver, and kidneys were harvested and homogenized in D-PBS using 1.4 
mm acid washed zirconium grinding beads (OPS Diagnostics LLC, Lebanon, NJ) with a 
FastPrep-24 Automated Homogenizer (MP Biomedicals, Santa Ana, CA). Tissue 
homogenate fluorescence was measured using a Synergy H4 BioTek plate reader and 
fluorescent tracer standard curves were made in individual tissue homogenates. Prism 6 
(GraphPad, LaJolla, CA) was used to calculate exposure (as area under the curve from 1-
72 hours, AUC) as well as the fluorescent tracer half-life of residence within the site of 
injection using one-phase decay least-squares regression. Error propagation analysis was 
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used to calculate the standard error of AUC measurements. Concentrations are presented 
as the percent of tracer injection amount per tissue volume calculated from the respective 
tissue’s weight and assuming a density of water.  
3.2.7 Statistical Analysis 
Data are represented as the mean with S.E.M. and statistics were calculated using 
Prism 6. Statistical significance was defined as p < 0.05 following two-way ANOVA and 
post-hoc analysis with Tukey tests or one-way ANOVA followed by Fisher’s Least 
Significant Difference (LSD) test. One, two, three, and four symbols denoting statistical 




3.3.1 Tumor Secreted Soluble Factors and Fluorescent Tracer Representatives 
As a proxy for TSF produced in vivo, we first analyzed the size distribution of 
protein- and DNA-containing species within B16F10 cell-conditioned media. Using 
gravity column chromatography, we found protein and DNA to be contained in fractions 
in both the large (fractions 6-10 corresponding to hydrodynamic diameters ranging from 
~10-1000 nm) and small (fractions 15-24 corresponding to sizes < 10 nm) hydrodynamic 
size regimes (Figure 3.1A). We thus chose to model this large size range of physiological 
TSF that also corresponds to the broad size range of various anti-cancer therapeutic 
agents using a panel of near-infrared fluorescently labeled tracers (Table 3.1) verified 
free of unconjugated dye (Figure 3.2) with similar physiological levels of negative charge 
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(Table 3.1) spanning from 5 to 500 nm in hydrodynamic diameter (Figure 3.1B): 10kDa 
(5 nm) and 500kDa (30 nm) chain-like dextrans were chosen to represent small peptides 
and larger protein complexes while 50 and 500 nm polystyrene spheres were selected to 
model exosomes or nanoparticles and microvesicles or microparticles, respectively 
(Figure 3.1B-C).  
 
Figure 3.1 Analysis of B16F10 Conditioned Media and Fluorescent Tracers. (A) Size 
exclusion chromatography analysis of protein and DNA containing B16F10 
conditioned media fractions and fluorescent tracers. (B) Physiological TSF, typical 
anti-cancer therapeutic agents, and their size-matched tracers used for this study. 
(C) Dynamic light scattering measurements of tracers. 
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Figure 3.2 Preparative and analytical size-exclusion chromatography demonstrating 
separation of free dye from TSF tracer dextran conjugates. 
3.3.2 Size-dependent Rates and Extents of Clearance from the Naïve Skin 
To determine the rate of clearance from the skin and resulting distribution into 
disseminated tissues, we co-infused the fluorescent tracer cocktail into the lateral dorsal 
skin of naïve animals and analyzed at timescales over which passive drainage (1-24 hr) 
versus active cell mediated trafficking (72 hr) from peripheral tissues transpire [71, 100]. 
Tracer fluorescence was quantified via endpoint analysis of homogenized individual 
tissues rather than commonly used whole animal imaging techniques, providing superior 
spatial resolution and limits of detection (Table 3.2). As such, the amount and resulting 
concentrations of infused tracers within various tissue compartments could be quantified 









10 kDa Dextran 
(610/630) 
500 kDa Dextran 
(700/720) 
50 nm Sphere 
(660/680) 
500 nm Sphere 
(580/610) 
Lymph Node 290 180 5.0 3.72E-04 
Tumor 7000 280 30 4.54E-03 
Spleen 660 210 10 3.40E-03 
Lung 1460 460 6.0 1.88E-03 
Liver 10000 800 180 2.60E-02 
Kidney 3350 270 30 4.35E-03 
 
We found the 5 nm tracer to be most extensively cleared, with less than 10% of 
the injected amount retained after 1 hour p.i. whereas the tracers of larger sizes 
experienced much more restricted clearance (Figure 3.3A). In terms of the percent 
remaining 72 hours after injection (Figure 3.3B) and tissue half-life (Figure 3.3C), we 
found a linear increase with respect to tracer size up to 50 nm. For example, the amount 
remaining in the dermis after 72 hours was only 3% of the initial injection for the 5 nm 
tracer, but approximately 50 and 80% for the 30 versus 50 and 500 nm tracers, 
respectively (Figure 3.3B). The 5 nm tracer was also cleared most quickly, with a 
calculated retention half-life of only about 10 minutes, while the larger tracers were 
transported away more slowly with retention half-lives on the order of tens to hundreds of 
hours (Figure 3.3C).  
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Figure 3.3 Size-dependent clearance and biodistribution of tracers into local versus 
systemic tissues after intradermal injection in naïve mice. Time-resolved retention 
profiles (A), % remaining after 72 hr (B), and retention half-lives (T1/2, C) of 
tracers within skin. Time-resolved accumulation (D) and exposure (E-F) of tracers 
in dLN and non-dLN (E) versus systemic tissues including the spleen, lungs, liver, 
and kidneys (F). E, *** indicates significance relative to all other tracers by one-way 
ANOVA and post-hoc Fisher’s LSD tests. F, *** indicates significance relative to all 
other tracers and kidneys vs all other tissues for 5 nm tracer by two-way ANOVA 
and post-hoc Tukey’s tests. AUC from 1-72 hr p.i. Tracer concentrations in dLN (G) 
and systemic tissues (H). (I) Ratio of accumulating tracer concentrations within dLN 
to systemic tissues. G-I, * indicates significance relative to all other tracers at the 
same time point by two-way ANOVA and post-hoc Tukey’s tests. § indicates 
significance for 500 nm tracer relative to all other time points (H-I), ‡ for 50 nm 
tracer relative to all other time points in (G,I) but only vs 4 hr in (H), † for 30 nm 
tracer vs 1 hr in (G) but relative to all other time points in (H,I), and ¶ for 5 nm 
tracer vs 1 and 4 hr in (G) by one-way ANOVA and post-hoc Fisher’s LSD tests; 
results representative of n=9 mice per group performed in three independent 
experiments. 











Concurrent with analyzing their clearance from naïve skin, we measured the 
accumulation of infused tracers within dLN or into systemic tissues, including the lungs, 
spleen, liver, and kidneys, in excised tissue homogenates via fluorescence. We found that 
30 nm dextran accumulated most appreciably within dLN at all measured time points 
(Figure 3.3D). This resulted in a dramatically higher exposure (% injected) of the 30 nm 
tracer within dLN relative to both smaller (5 nm) and larger tracers (50 and 500 nm) 
tested here (Figure 3.3E). No exposure (% injected) was seen in non-dLN (Figure 3.3E), 
confirming this clearance was lymphatic mediated. Conversely, 5 nm dextran was most 
appreciably found within systemically distributed tissues (lungs, spleen, liver, and 
kidneys) (Figure 3.3D) resulting in the highest levels of total systemic exposure (% 
injected) of all tracers (Figure 3.3F). Exposure (% injected) in these tissues for the 5 nm 
tracer was highest in the kidneys whereas larger tracer sizes accumulated predominantly 
in the liver (Figure 3.3F). When accounting for tissue volumes, these biodistribution 
profiles resulted in appreciable levels of dLN accumulation for 50 and 500 nm tracers 
only after 72 hr p.i., suggesting their transport was primarily via cell-mediated uptake and 
migration to dLN (Figure 3.3G). 5 nm dextran also accumulated in dLN, though to a 
more modest extent, peaking at 24 hr p.i., suggesting a mechanism of passive lymphatic 
drainage (Figure 3.3G). Corroborating previous reports [101], 30 nm dextran, on the 
other hand, demonstrated sustained accumulation within dLN at significantly higher 
levels (5-20 fold) relative to all other tested tracer sizes at all tested time points p.i. 
(Figure 3.3G). By comparison, all tracer sizes exhibited dramatically lower 
concentrations in systemic tissues (Figure 3.3H). Over the size regimes tested, we 
consequently found a significant enrichment in tracer concentrations within dLN relative 
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to systemic tissues (Figure 3.3I). Most strikingly, the 30 nm tracer exhibited a three to six 
order of magnitude increase in dLN concentration relative that seen in systemic tissues at 
all measured time points and 50 and 500 nm tracers were found to be enriched by two to 
three orders of magnitude at 72 hours p.i. (Figure 3.3I).  
3.3.4  Remodeling of the Tumor Vascular Plexus with Tumor Growth 
In order to evaluate the effect of melanoma growth and remodeling on tracer 
clearance and resulting biodistribution from the dermis, we next evaluated the changes in 
the dorsolateral dermal vasculature induced by growth of the B16F10 melanoma in 
immune-competent C57Bl6 mice (Figure 3.4A). The melanoma vascular plexus exhibited 
branching irregularities as early as day 5 post tumor implantation and by day 7 exhibited 
a striking hyper-vascularized expansion (Figure 3.4B). This was reflected in a more than 
doubling of vascular volume and surface area between days 5 and 7 post tumor 
implantation (Figure 3.4C). The mean vessel diameter also increased throughout the 
course of tumor growth (p<0.05) to grow by as much as 75% by day 9 post tumor 
implantation (Figure 3.4D). The blood vasculature of growing B16F10 melanomas also 
exhibited a dramatic enhancement in permeability that increased with time post tumor 
implantation (p<0.01), as demonstrated by the accumulation of i.v. infused 5 nm dextran 
within the tumor interstitium at 4 hours p.i. (Figure 3.4E). 
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Figure 3.4 B16F10 melanoma vascular remodeling. Representative B16F10 
melanoma growth curve (A) and micro-computed tomography 3D reconstructions 
of the tumor blood vasculature (B). Mean vascular volume (C), vascular surface 
area (SA, C), and vessel diameter (D). (E) Intratumoral accumulation of i.v. injected 
dextran. * indicates significance relative to day 0 (naïve) and † relative to day 5 by 
ANOVA and post-hoc Tukey’s tests; n=3-5 mice per group.  
3.3.5 Malignancy Increases Locoregional Tracer Exposure 
Given these remodeling responses, we evaluated the rate of clearance from the 
growing melanomas at prescribed time points p.i. We found exposure (% injected) of 30-
500, but not 5, nm tracers in all analyzed tumors was higher relative to that of naïve skin 
tissues (Figure 3.5A). When analyzed with respect to tumor stage, 50 and 500 nm tracers 
exhibited higher levels of tumor exposure (% injected) relative to naïve skin as early as 5 
days post tumor implantation whereas increased tumor exposure (% injected) began only 
at day 7 post tumor implantation for 30 nm dextran (Figure 3.5B). Although not 
statistically significant, trends demonstrated that as a result of the slower clearance 
profiles from malignant tissues, the exposure (% injected) within tumors increased by 
only 20% with malignant progression for the 500 and 50 nm tracers for days 5, 7 and 9 






9 (Figure 3.5C). 5 nm dextran exposure (% injected) in the tumor also increased by ~60% 
at day 5 post tumor implantation but then decreased thereafter, reaching ~40% of that 
seen in naïve skin in day 9 tumors (Figure 3.5C).  
  
Figure 3.5 Tracer exposure is modestly increased in the tumor interstitium. (A-B) 
Tracer exposure within the skin or melanoma site of injection. (C) Tracer exposure 
resolved by tumor day normalized to levels in naïve skin. AUC from 1-72 hr p.i. 
Results representative of n=6-9 mice per group performed in two to three 
independent experiments. 
3.3.6 Tumor Progression Reduces dLN Accumulation and Increases Systemic Exposure 
to Tumor-derived Factors 
We next analyzed the biodistribution of systemically distributed tracers after 
infusion. At day 5 and 7 post tumor implantation we noted a surprising increase in 
exposure (% injected) in systemic tissues, which increased further by day 9 post tumor 
implantation for 5 nm dextran but not for other larger tracers (Figure 3.6A). Similar to the 




the most significant exposure (% injected) to 30, 50 and 500 nm tracers was the liver 
(Figure 3.6B). Contrastingly, whereas the 5 nm dextran disseminated primarily to the 
kidneys when cleared from the naïve skin tissue (Figure 3.3F), 5 nm dextran was found to 
also accumulate in tumor-bearing animals in the liver (Figure 3.6B). These results 
corresponded to increases in the maximum concentrations of tracer accumulating in the 
spleen, lungs, liver, and kidneys (Figure 3.6C). Notably, the maximum concentrations of 
500 and 50 nm tracers were significantly non-zero in the lung tissue of day 9 melanoma-
bearing animals in distinct contrast to naïve and day 5 and 7 post tumor implantation 
animals (Figure 3.6C). These concentration profile changes resulted in an initial increase 
in exposure (% injected) of 500 and 50 nm tracers in the spleen and 500 nm tracer 
exposure (% injected) in the liver days 5 and 7 post tumor implantation that was greatly 
diminished in day 9 tumors (Figure 3.6D). Exposure (% injected) in day 9 tumor bearing 
animals was reduced relative to naïve animals with respect to 30 and 5 nm tracers in the 
spleen and the 30 nm tracer in the liver, whereas liver exposure (% injected) to the 5 nm 
tracer was elevated relative to that seen in naïve animals at all tumor stages analyzed 
(Figure 3.6D). Accumulation of 30 nm dextran in the spleen and liver also occurred at 
earlier times post-injection in day 7 and 9 melanoma bearing animals, shifting from a 24 
hour p.i. concentration peak in naïve animals to a peak in concentration at 1-4 hour p.i. 
(Figure 3.6E).  
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Figure 3.6 Fluorescent tracers exhibit increased accumulation in systemic tissues 
with tumor progression. (A-B) Total tracer exposure in systemic tissues including 
the spleen, lungs, liver, and kidneys. ** indicates significance for day 9 vs naïve for 
same tracer. *** indicates significance for 5 nm tracer at day 9 in kidney vs all other 
groups by two-way ANOVA and post-hoc Tukey’s tests. (C) Maximum tracer 
concentrations measured over 72 hr experimental timeframe. * indicates 
significance for day 9 vs all other groups of same tissue and tracer, † p<0.001 for 
day 5 vs all other groups of same tissue and tracer, and § p<0.001 for day 7 vs all 
other groups of same tissue and tracer by one-way ANOVA with post-hoc Fisher’s 





resulting from melanoma growth with respect to exposure measured after injection 
in naïve skin. (E) Time-resolved concentration of 30 nm tracer in spleen and liver 
tissues. † p<0.05 for naïve 24 hr time point vs 1 and 4 hr naïve time points, ** p<0.01 
for day 9 4 hr time point vs all other day 9 time points, * p<0.05 for naïve 24 hr time 
point and day 9 four hr time point vs all other by one-way ANOVA with post-hoc 
Fisher’s LSD tests. AUC from 1-72 hr p.i. Results representative of n=6-9 mice per 
group performed in two to three independent experiments. 
When analyzed in a time-resolved fashion, as in naïve animals (Figure 3.3G), 
clearance through active cell-mediated trafficking via the lymphatics remained 
appreciable in day 5 tumor bearing animals, as indicated by significant concentrations of 
the 500 and 50 nm tracers within dLN only 72 hours p.i (Figure 3.7A-B). This transport 
activity, however, was abolished in day 7 and 9 tumors (Figure 3.7A-B). Similarly, 
passive lymphatic drainage was also decreased with tumor progression, as indicated by 
reduced levels of sustained 5 and 30 nm tracer concentrations in dLN at all times p.i. 
(Figure 3.7C-D). As a result, dLN exposure (concentration) to all tracer sizes was 
significantly attenuated in tumor-bearing animals relative to naïve animals (Figure 3.7E-
F). Specifically, relative dLN exposure (concentration) to all tracer sizes decreased 
rapidly with tumor progression, reaching near zero levels by day 7 for 5 and 50 nm 
tracers and for all tracer sizes at day 9 post tumor implantation (Figure 3.7F). Notably, 
however, exposure (concentration) of 30 nm tracers at even their most attenuated levels 
(day 9 post tumor implantation) remained significantly higher (nearly two-fold) than that 
of all other tracer sizes in even naïve animals (Figure 3.7E).  
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Figure 3.7 Tumor progression reduces tracer accumulation within TDLN. (A-D) 
Time-resolved tracer concentrations within TDLN. † indicates significance relative 
to all other time points for same group, ¶ relative to 1 hr time point for same group, 
* relative to naïve, and § relative to naïve and day 5 groups by one-way ANOVA 
with post-hoc Fisher’s LSD test. Tracer exposure within dLN is attenuated by 
tumor growth (E) relative to naïve skin (F). * indicates significance relative to all 
other tracers within same tumor day group by one-way ANOVA with post-hoc 
Fisher’s LSD test. AUC from 1-72 hr p.i. Results representative of n=6-9 mice per 
group performed in two to three independent experiments. 
When comparing the relative levels of exposure (concentration) of different tracer 
sizes with respect to tumor stage in dLN versus systemic tissues, we found an increase in 
the relative extents of transport of tracers 500, 50, and 5 nm in size into systemic tissues 
as indicated by a decreasing ratio of dLN to systemic concentration AUC (Figure 3.8A-
C). While the 30 nm tracer exhibited a reduced level of accumulation within dLN post 
tumor injection (Figure 3.7E-F), exposure (concentration) in dLN still remained two to 
three orders of magnitude higher relative to that seen in systemic tissues (Figure 3.8A). 
When normalized relative to the measured ratios of naïve animals, the 500 nm tracer 
experienced the most significant redirection into systemic relative to dLN tissues at all 





exhibited a bias towards increased accumulation in systemic tissues rather than dLN by 
days 7 and 9 post tumor implantation (Figure 3.8B). Changes in the accumulation profile 
of 30 nm dextran, however, were less pronounced, even in day 9 tumor-bearing animals 
(Figure 3.8B). This is because whereas for 500, 50, and 5 nm tracers an increasing 
proportion accumulates in systemic tissues as the disease progresses, the 30 nm tracer 
primarily accumulates (>99%) instead in dLN at all tumor growth stages analyzed 
(Figure 3.8C). 
When assessing the relative exposure of each tracer size in individual tissues, we 
found changes in size-dependent accumulation profiles that result from tumor formation 
and growth, despite no substantial differences in the relative levels of exposure within the 
skin versus tumor after injection (Figure 3.8D). Specifically, 500, 50, and 30 nm tracers 
each accounted for approximately a third of the total exposure at the site of injection 
irrespective of tumor stage (Figure 3.8D). The 5 nm tracer on the other hand exhibited 
little to no local exposure (Figure 3.8D), consistent with its rapid clearance (Figure 3.3A). 
Irrespective of tumor stage, 30 nm was the predominant tracer size that accumulated 
within dLN and the proportion of 30 nm tracer of total accumulating within the dLN 
increased with tumor growth (Figure 3.8D). Strikingly, the livers of melanoma-bearing 
animals day 5 and 7 post tumor implantation exhibited profiles of exposure strikingly 
similar to those seen within the tumor (albeit with higher 5 nm tracer levels) rather than 
naïve liver (Figure 3.8D). Day 9, but not 5 or 7, melanoma-bearing animals also exhibited 
lung exposure profiles more similar to that of the tumor rather than naïve lung, with 
exposure to only higher molecular weight tracers (equally shared between 500 and 50 nm 
tracers) versus predominantly 5 nm, respectively (Figure 3.8D). 
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Figure 3.8 Melanoma disease progression has no effect on the proportion of 30 nm 
tracer exposure in TDLN while increasing the exposure of other tracer sizes in 
systemic tissues. (A) Ratio of accumulating tracer concentrations within dLN to 
systemic tissues with respect to tumor stage and (B) normalized to naïve skin. (C) 
Proportion of dLN versus systemic tissue exposure (concentration). (D) Proportion 
of accumulating tracers with respect to hydrodynamic size. AUC from 1-72 hr p.i. 
Results representative of n=6-9 mice per group performed in two to three 
independent experiments. 
3.4 Discussion 
The deleterious effects of cancer are not limited to the primary tumor itself, as 
evidenced by the sentinel lymph node’s role in tumor immune suppression [20, 48] as 
well as the high number of cancer-associated complications and mortalities associated 
with both metastasis [102, 103] and thrombosis [104, 105]. Distant intercellular signaling 




of sentinel lymph nodes [18], VEGFR1+ haematopoietic progenitor cell recruitment to 
pre-metastatic niches [5], and secretion of tumor-derived pro-coagulants and cytokines 
driving thrombosis [106]. Paracellular communication between cancer cells, their 
secreted factors, and the endothelium within the malignant melanoma microenvironment 
that regulate vascular permeability thus have a putative role in a myriad of pathways 
implicated in disease progression.  
In numerous cancer types including melanoma [46], breast carcinoma [107-109], 
and prostate carcinoma [110], amongst others [111, 112], circulating inflammatory 
cytokine [110], chemokine [108, 113], enzyme [107], exosome [46], and/or microvesicle 
[111] levels and qualities are altered relative to healthy controls and with respect to 
disease stage in both patients and pre-clinical tumor models. These changes have been 
attributed to both higher production of such factors within the tumor [5, 107, 113] and 
extratumoral host tissue response to tumor growth [114]. Our data support the notion that 
increased systemic exposure to TSF may accompany tumor growth (Figure 3.6) in a 
manner independent of TSF abundance since higher levels of exposure in systemic 
tissues were noted in animals with late stage malignancies despite the same amount of 
tracer being infused into each animal. These changes occurred before formation of 
apparent metastases, suggesting that altered rates, magnitudes, and mechanisms of TSF 
clearance arise as a result of tissue remodeling within the primary tumor 
microenvironment. 
Increased systemic exposure to intratumorally infused tracers (Figure 3.6) 
accompanied enhanced intratumoral accumulation of a systemically administered tracer 
(Figure 3.4E). For example, in as early as day 5 lesions, the exposure of spleen and liver 
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tissues to large 500 and 50 nm tracers was elevated (Figure 3.6B) approximately two- to 
30-fold (Figure 3.6D). Reduced exposure was seen in animals with more advanced (day 
9) lesions (Figure 3.6B-D) and is likely the result of interstitial matrix remodeling within 
the tumor [60, 68] leading to larger tracer entrapment since levels of systemic exposure to 
5 nm dextran continued to increase at this tumor stage (Figure 3.6A-B). Liver and spleen 
accumulation of large (30-500 nm) tracers peaking at 1-4 hours p.i. in animals bearing 
early stage (day 5 and 7) malignancies rather than 24 hr in naïve animals (Figure 3.6E) 
also supports the concept that these increases in systemic exposure were the result of 
direct tracer uptake into the blood rather than enhanced lymphatic clearance and return to 
the systemic circulation. Increased tumor vascular permeability, as has been previously 
reported for this and other tumor models [115-117], thus may also enhance blood-
mediated clearance that manifests as increased tumor-derived factor exposure in systemic 
tissues. Injection resulted in a small (~ 1 mmHg) increase in interstitial pressure that was 
similar between naïve and tumor tissues that returned to pre-injection levels after removal 
of the needle (data not shown). However, it should be noted that measured tracer 
pharmacokinetics could differ from those of native tissues in vivo. 
Our data support the concept that tumor growth and remodeling confer the potential 
of TSF to mediate signaling in distant tissues that is absent in healthy animals. Tumor-
secreted microparticles, including exosomes and microvesicles, which range in 
hydrodynamic diameter from 30-100 nm and 100-1000 nm [118], respectively, have 
reported capacities to support neovascularization [119], extracellular matrix remodeling 
[28], and immunomodulation [109]. Here we demonstrate 500 and 50 nm tracers cleared 
from the tumor to accumulate at elevated levels in the liver and spleen (Figure 3.6D). 
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Moreover, we found these tracers to accumulate appreciably within the lungs of animals 
with advanced (day 9) malignancies (Figure 3.6C), a redirection in their biodistribution 
that occurred concurrently with attenuated transport to TDLN (Figure 3.7). TSF signaling 
that would take place within dLN in naïve animals appears to instead be redirected to 
lungs of tumor-bearing animals. Small to intermediate size biomolecules secreted by 
tumors such as peptides, proteins, and other biopolymers have also been implicated in a 
multitude of roles that exacerbate disease progression [109, 113]. We provide evidence 
that exposure of small molecules ~5 nm in hydrodynamic size is also appreciably 
increased in systemic relative to dLN tissues in tumor-bearing animals (Figure 3.6). 
Overall, accumulation of 500, 50 and 5 nm tracers shifted significantly from dLN to 
systemic tissues over the time course of disease progression evaluated here (Figure 3.8). 
As a result, profiles of TSF tracer accumulation in the liver and lung diverged from that 
seen in naïve animals and instead more closely mirrored those of the primary tumor 
(Figure 3.8D). This suggests that signaling processes active within the tumor 
microenvironment have the potential to be operational in systemic tissues of melanoma-
bearing animals and may significantly regulate and negatively influence the course of 
disease progression. They also indicate that therapeutic agents administered 
intralesionally, for example oncolytic immunotherapy talimogene laherparepavec [120], 
may also result in significant signaling activity outside of the primary tumor in 
distributed systemic tissues. 
The effect of melanoma growth on tracer clearance and biodistribution diverged 
with respect to its effects on blood versus lymphatic mediated transport. As opposed to 
increased levels of uptake via the blood vasculature, melanomas at day 7 and later post 
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implantation demonstrated a dramatic attenuation in lymphatic function, which is 
regulated by local inflammatory [121] and biomechanical [122] signaling, as evidenced 
by reduced levels of tracer accumulation within dLN relative to that seen in naïve animals 
(Figure 3.7C-F). Parallel reductions in lymphatic-mediated cellular migration to dLN, 
which are regulated by flow-organized chemokine gradients and vascular signaling [123-
125], were also observed (Figure 3.7A-B, E-F). These reductions coincided with tumor 
vascular volume and surface area doubling relative to naïve skin tissues at day 7 and 9 
post tumor implantation (Figure 3.4C). In line with previous reports [101], the 
predominant lymph-draining tracers were found to be 30 nm in size in both healthy 
(Figure 3.3D-E,G) and malignant (Figure 3.7E) skin. Interestingly, despite reduced total 
levels of dLN accumulation, the relative accumulation of 30 nm tracer in dLN relative to 
systemic tissues remained relatively unchanged. This indicates that despite reductions in 
lymphatic transport function (Figure 3.7), TSF approximately 30 nm in diameter such as 
exosomes and large protein complexes continue to primarily signal extratumorally within 
TDLN (Figure 3.8C-D). These results also underscore the potential utility of drug 
formulations ~30 nm in size to accumulate substantially in sentinel lymph nodes when 
intralesionally administered.  
3.5 Conclusions 
In summary, we have demonstrated that tracer clearance from primary melanomas 
is concurrently altered with tumor vascular remodeling and results in distinct 
biodistribution profiles relative to those seen in healthy animals. These are the first 
measurements juxtaposing the size-resolved biodistribution profiles of tumor-derived 
factors in naïve versus tumor-bearing animals to elucidate the influence of disease. Our 
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results highlight the role lymphatic drainage function plays in enriching TSF 
accumulation in dLN. Furthermore, these data suggest that melanoma growth 
redistributes TSF signaling to systemic tissues by compromising transport barriers in 
healthy tissues and that despite attenuation of total levels of accumulation, previously 
developed principles of size-dependent lymph node drug targeting are conserved in 
melanomas over the course of disease progression. Our findings contribute evidence that 
tumor vascular remodeling not only manifests in the enhanced permeability and retention 
effect in solid tumors, but also increased access of factors from the tumor interstitium to 
systemically distributed tissues. These results will inform the rational design of sentinel 
lymph node-targeted drug delivery strategies as well as future studies on how 




CHAPTER 4. Flexible macromolecule versus rigid particle retention 
in the injected skin and accumulation in draining lymph nodes are 
differentially influenced by hydrodynamic size [179] 
4.1 Introduction 
Immunotherapy is increasingly employed for the treatment of a variety of 
pathologies, such as cancer and autoimmune disease. Accordingly, biomaterial-based 
formulation approaches have been explored to improve the bioactivity and therapeutic 
efficacy of numerous immunotherapeutic interventions.[126-128] These include 
strategies to co-deliver multiple immunotherapeutic drugs,[129, 130] provide sustained 
and/or controlled drug release,[131-133] and improve drug circulation half-lives,[129, 
134, 135] the success of which are critically influenced by the adequate and selective 
accumulation or retention of drug within target tissues. To this end, biomaterials have 
been used to improve drug bioavailability within healthy[136, 137] and diseased 
skin,[138-140] key targets in vaccine, skin graft, and cancer immunotherapy applications. 
Notwithstanding approaches leveraging the enhanced permeability and retention effect 
for tumor-enhanced delivery after intravenous injection, dermal delivery is largely 
accomplished via direct injection.[138, 139] Consequently, designing drug carriers to 
achieve prolonged retention at the site of injection has been widely explored to improve 
drug bioavailability and potency.[136, 139] 
LNs are emerging as key immunotherapeutic targets given their role in directing 
adaptive immunity and tolerance.[70, 141, 142] Notably, the efficacy of infectious 
disease and cancer vaccines is improved by LN-targeting[48, 80, 91, 143, 144] resulting 
from the localized modulation of immunological signaling to alter adaptive immune 
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response. As an example of such an approach, delivery to melanoma dLN mediated by 
lymphatic-draining synthetic polymer nanoparticles improves adjuvant activity, in 
particular increasing dendritic cell maturation as well as Th1 and anti-tumor CD8+ T cell 
immunity, resulting in reduced tumor growth, a response lost by adjuvant delivery in a 
non-targeted manner or to LN not draining the melanoma.[48] In another example, 
corticosteroid delivery to skin graft dLN mediated by encapsulation within block co-
polymer micelles has demonstrated success in delaying rejection.[145] Localizing drug 
activity to dLN can thus provide significant advantages to immunotherapy in improving 
immunological outcomes in addition to achieving dose sparing to minimize off target 
effects/toxicities.[146, 147]  
Given the local immunological signaling associated with pathogenesis in both the 
diseased skin and its dLN, therapeutic immunomodulation in either the skin or its dLN or, 
conversely, in both tissues simultaneously is potentially desirable for numerous 
therapeutic scenarios. However, despite recent advances in targeted immunotherapeutics 
using biomaterials,[143, 144, 146, 148] there is limited understanding of how carrier 
design simultaneously affects retention and accumulation in both the skin injection site 
and its dLN. Previous studies have explored the effects of biomaterial carrier size[91, 92], 
charge[149, 150], hydrophobicity[151, 152], and shape[153, 154] on various aspects of 
transport, cellular uptake, and adaptive immune response. How the coupled effects of 
both size and form influence carrier transport, especially with respect to dermal and dLN 
targeted applications, however, remains to be described. Since biomaterial-based delivery 
systems are increasingly explored for immunotherapeutic delivery[128, 155], we sought 
to analyze the differences in profiles of spherical particulate versus macromolecular 
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retention as a function of hydrodynamic size in the site of dermal injection as well as the 
corresponding extent of accumulation in dLN and systemic off-target tissues. This was 
achieved by implementing a panel of tracers comprised of inert polymers (polystyrene 
particles and dextran macromolecules) that are resistant to hydrolysis and proteolytic 
degradation that span a size range of widely used drug carrier systems and are labeled 
with fluorophores with minimal tissue absorbance and spectral overlap.[62] Tracers were 
intradermally infused into naïve C57Bl6 mice and their biodistribution among the skin 
injection site, dLN, and systemic tissues was examined by endpoint analysis and 
fluorescent measurement of homogenized tissues. Our results demonstrate that chain-like, 
flexible macromolecular but not rigid, spherical particulate retention within the skin 
injection site is size-dependent, that enrichment within the skin relative to systemic 
tissues increases with size for both macromolecules and particles, and macromolecules 
accumulate in dLN more extensively and selectively than rigid, spherical particles. 
4.2 Materials and Methods 
4.2.1 Fluorescent Tracers 
FITC (Fluorescein isothiocyanate) labeled 2 MDa dextran was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 500, 50, and 25 nm fluorescent (580/610 nm, 
660/680 nm, and 625/645 nm excitation/emission, respectively) carboxylate-modified 
polystyrene microspheres and 70 and 40 kDa fluorescent (490/520 nm and 555/585 nm 
excitation/emission, respectively) dextrans were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). 500 kDa or 10 kDa amine-dextrans (Sigma-Aldrich) 
were covalently labeled by incubation in 0.1 M NaHCO3 buffer at pH 8.4 for 4 hr with 
Alexa Fluor 700 N-hydroxysuccinimide (NHS) ester or Alexa Fluor 610-X NHS-ester 
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dye (Thermo Fisher Scientific), respectively. Individual fluorescent dextran conjugates 
were purified from unreacted free dye and confirmed to be free of unconjugated dye by 
Sepharose CL-6B gravity column chromatography as previously described.[62] All 
reagents were maintained and used under sterile conditions. Hydrodynamic sizes of 
individual fluorescently conjugated tracers were measured by dynamic light scattering 
using a Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, United Kingdom), except 
for the 25 nm polystyrene spheres for which the manufacturer’s sizing data was used due 
to fluorophore incompatibility with our Zetasizer Nano ZS.  
4.2.2 Biodistribution Experiments and Analysis 
C57Bl6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). 
All protocols were approved by the Institutional Animal Care and Use Committee. 30 µL 
of fluorescent tracer solution normalized for equivalent material volumes using the 
respective radius or hydrodynamic radius (either 1.2x10
8
 500 nm spheres, 7.9x10
11
 50 nm 
spheres, 23.8 µg of 500 kDa AF700-dextran, and 3 µg of 10 kDa AF610-dextran (n=9 for 
24 hr, n=9 for 72 hr in 6 independent experiments); or 8.3x10
11
 25 nm spheres and 1.38 
µg of 2 MDa FITC-dextran (n=3 for 24 hr, n=6 for 72 hr in 4 independent experiments); 
or 8.3x10
11
 25 nm spheres, 1.93 µg of 40 kDa TRITC (Tetramethylrhodamine 
isothiocyanate)-dextran and 0.81 µg of 70 kDa FITC-dextran (n=3 for 24 hr, n=3 for 72 
hr in 4 independent experiments)) in saline was infused intradermally into the shaved 
lateral dorsal skin using a syringe pump at a rate of ~300 nL per sec as previously 
described.[62] Tracers with similar labels were injected into separate animal cohorts. 24 
or 72 hr post injection (p.i.), the brachial LNs ipsilateral and contralateral to the site of 
injection, the skin at the injection site, and the spleen, lungs, liver, and kidneys were 
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harvested and homogenized in D-PBS using 1.4 mm acid washed zirconium grinding 
beads (OPS Diagnostics LLC, Lebanon, NJ, USA) with a FastPrep-24 Automated 
Homogenizer (MP Biomedicals, Santa Ana, CA, USA). Tissue homogenate fluorescence 
was measured using a Synergy H4 BioTek plate reader (BioTek Instruments Inc.), 
compensation for fluorescence overlap was applied, and fluorescent tracer standard 
curves were made in individual tissue homogenates. Concentrations were calculated as 
the percent of tracer injection amount per whole tissue volume (%/mL). Prism 6 
(GraphPad Software Inc., La Jolla, CA, USA) was used to calculate exposure from the 
area under the curve (AUC) of tracer concentrations measured between 0 and 72 hr. Error 
propagation analysis was used to calculate AUC standard error. Systemic tissues used in 
ratio calculations included the spleen, lungs, liver, and kidneys. Due to high systemic 
tissue (spleen, lungs, liver, and kidneys) autofluorescence around FITC wavelengths, 
FITC labeled tracers (70 kDa and 2 MDa dextrans) were not included in concentration 
ratio analyses. 
4.2.3 Statistical Analysis 
Data are represented as the mean with standard error. Statistics were calculated 
and linear regressions were performed using Prism 6 (GraphPad Software Inc.). 
Statistical significance was defined as p < 0.05 following Mann-Whitney U tests or one-
way ANOVA followed by Fisher’s Least Significant Difference (LSD) test. One, two, 
and three symbols denoting statistical significance represent p < 0.05, 0.01, and 0.001 
respectively, unless otherwise specified.  
4.3 Results 
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4.3.1 Skin Retention versus Exposure in Systemic Tissues Increases with Increasing 
Tracer Size 
A panel of eight dextran and polystyrene sphere tracers spanning 5-54 and 25-500 
nm in hydrodynamic diameter, respectively (Figure 4.1A-B), was used to interrogate the 
effect of size versus form on skin retention and biodistribution. Because we wanted to 
explore whether size-based principles of dLN drug delivery are similar for 
macromolecule- and particle-based delivery systems, two size-matched tracer subsets in 
the size range of passive lymphatic transport (25 nm polystyrene vs 30 nm dextran and 50 
nm polystyrene vs 54 nm dextran) were used to enable the direct comparison of carrier 
form on dermal retention and dLN accumulation. 5 nm dextran and 500 nm polystyrene 
spheres were also included as benchmarks for modes of tracer transport from the 
interstitium besides passive lymphatic uptake for tracers with low retention at the site of 
injection due to absorption into the bloodstream and requiring active cell-mediated 
transport from the site of injection to the dLN, respectively. Measured profiles of 
biodistribution (Figure 4.2A) and size-exclusion column chromatography elution (Figure 
4.2B) confirmed that individually versus co-infused tracers behaved identically with 
minimal to no interaction or aggregation effects.  
 
Figure 4.1 Measured hydrodynamic sizes (A) of fluorescent dextran (Dex) and 
polystyrene sphere (PS) tracer panel (B). 
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Figure 4.2 Characterization of individual versus mixtures of fluorescent tracers. (A) 
Measured dLN accumulation and dermal retention of dextran (Dex) and 
polystyrene spheres (PS) either individually infused into the dorsal skin of separate 
animals or with tracers mixed together and co-infused into the dorsal skin. (B) 
Comparison of tracer molecules after addition to a CL-6B column (Sigma-Aldrich) 
individually or mixed. 
After infusion into the skin, the smallest (5 nm) dextran was cleared most quickly 
from the injection site, with less than 5% of the injected amount remaining after 24 hr 
and only around 3% left at 72 hr p.i. (Figure 4.3A). In contrast, around 20-40% of the 10 
and 12 nm dextrans, 50% of the 30 nm dextran, and 85-100% of the 25-500 nm 
polystyrene sphere and 54 nm dextran tracers were measured in the dermis at 24 and 72 
hr p.i. (Figure 4.3A). As a result, the concentrations of the larger tracers (25, 50, 54, and 
500 nm) in the skin were significantly greater than that of the 5, 10, and 12 nm dextran at 
24 and 72 hr p.i. (Figure 4.3A). When also considering the concentration of tracer that 
accumulated in systemic tissues, the relative amount of tracer localized to the skin tissue 
surrounding the site of skin injection versus systemic organs increased with tracer size for 
dextrans 24 hr p.i. (p=0.050) and increased for both dextrans (p=0.006) and polystyrene 
spheres (p=0.001) 72 hr p.i. (Figure 4.3B). The fold enrichment also increased over time, 
presumably due to tracer elimination via excretion,[156] save for the 25 nm polystyrene 
spheres (Figure 4.3B).  
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Figure 4.3 Tracer retention in skin injection site increases with macromolecular but 
not particle hydrodynamic size but relative enrichment relative to systemic tissues 
increases with size for all tracer forms. (A) Percent of injection amount and 
resulting concentration of tracer within the dermal injection site 24 and 72 hr p.i.. 
(B) Ratio of tracer concentrations within the injected skin versus systemic tissues 
(spleen, lungs, liver, and kidneys) 24 and 72 hr p.i.. * indicates significance for 5-12 
vs 25, 50, 56, and 500 nm tracers at 24 and 72 hr p.i. by one-way ANOVA and post-
hoc Fisher's LSD tests. 
4.3.2 Accumulation within dLN is Greatest for Macromolecules and Increases with Size 
over 72 hr for Particles, albeit at Lower Levels of dLN-Specific Enrichment 
Relative to Macromolecules 
We next evaluated the extent of tracer accumulation within LN draining the 
injected skin. We found 30 nm dextran to exhibit the highest levels of dLN accumulation 
(~2% of injected tracer, approximately 10-20 fold higher than 5 nm dextran or 
polystyrene sphere tracers of other sizes) at 24 and 72 hr p.i. (Figure 4.4A). Dextrans 10, 
12, and 54 nm in hydrodynamic diameter also accumulated within dLN at appreciable 
levels (~1%), approximately half the amount of 30 nm dextran and when similarly sized, 
accumulated within LN at 5-10-fold higher levels relative to polystyrene spheres (Figure 
4.4A). 5 nm dextran, on the other hand, and 25, 50, and 500 nm polystyrene spheres 
accumulated in dLN the least at both 24 and 72 hr p.i. (Figure 4.4A). However, the 
difference in dLN accumulation between 24 and 72 hr p.i. significantly increased with 
polystyrene sphere size (p=0.037) presumably due to the increasing dependency on cell-
mediated trafficking to dLN,[92] with 500 nm polystyrene spheres exhibiting an almost 
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40 fold change (Figure 4.4B). The dextran tracers’ dLN accumulation, however, 
remained relatively constant from 24 to 72 hr p.i. (Figure 4.4B), suggesting a sustained, 
primarily passive lymphatic transport mechanism.[157] When compared to 
concentrations of tracers accumulating in systemic tissues, the 30 nm dextran 
demonstrated the highest dLN/systemic ratio at 24 and 72 hr p.i., around one to two 
orders of magnitude over that of the other dextran tracers, and interestingly, an order of 
magnitude higher than the similarly sized 25 nm polystyrene sphere tracer (Figure 4.4C). 
Considering concentrations of tracers accumulating in dLN relative to those in both skin 
and systemic tissues, dextran tracers exhibited an order of magnitude higher dLN 
enrichment, while the polystyrene tracers exhibited ratios at or less than one (Figure 
4.4D). We also found higher levels of 30 nm dextran tracer accumulation within dLN 
relative to the skin and systemic tissues as compared to size-matched polystyrene spheres 
at 24 hr p.i. (Figure 4.4D). 
 
Figure 4.4 Tracer accumulation within dLN is greatest for macromolecules, 
increases most appreciably over time with increasing particle size, and is the most 
specifically enriched relative to other tissues for macromolecules. (A) Percent of 
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injection amount and resulting concentration of tracer within dLN after dermal 
injection 24 and 72 hr p.i.. (B) Fold change in dLN tracer concentrations from 24 to 
72 hr p.i.. (C) Ratio of accumulated tracer concentrations within the dLN versus 
systemic tissues at 24 and 72 hr p.i.. (D) Tracer accumulation within dLN versus the 
skin injection site and systemic tissues at 24 and 72 hr p.i.. * indicates significant for 
25 vs 30 nm tracers by Mann-Whitney U tests, $ indicates significance for 500 vs 50 
and 25 nm tracers and # indicates significance for 30 vs 25, 50 and 500 nm tracers at 
24 and 72 hr by one-way ANOVA and post-hoc Fisher's LSD tests. The level of 500 
nm tracer accumulation within dLN at 24 hr p.i. was not detectable. 
4.3.3 Macromolecular but not Particulate Tracer Exposure within the Skin and dLN is 
Size-dependent 
Lastly, we sought to evaluate the effects of tracer size and form on total exposure 
(e.g., AUC) within the site of skin injection and the dLN from 0-72 hr p.i.. We found that 
skin exposure to injected dextran but not polystyrene sphere tracers increased with 
hydrodynamic size (p=0.022), reaching levels similar to that measured for all polystyrene 
tracers (Figure 4.5A). The dextrans 10-54 nm in hydrodynamic diameter also exhibited 
the highest levels of exposure within LN draining the injected skin, levels up to four-fold 
higher than those measured in the skin itself and greatest for the 30 nm dextran tracer 
(Figure 4.5B). Contrastingly, polystyrene sphere tracer exposure within the injected skin 
was similar to the largest (54 nm) dextran tested and dLN exposure was similar 
irrespective of size and at levels similar to those found for the dextran tracer exhibiting 
the lowest exposure in dLN (5 nm, Figure 4.5A, B). Accordingly, the exposure of size-
matched dextran and polystyrene tracers was similar in the skin but significantly greater 
(~3 to 10-fold) in dLN for both sizes of dextrans relative to the polystyrene spheres 
(Figure 4.5B-C). Taken together, when simultaneously considering exposure within the 
dLN versus skin, three separate tracer groups of dLN versus skin exposure emerged: the 
small macromolecule 5 nm dextran exhibited low exposure in both the dLN and skin, 
intermediate sized macromolecules (10-54 nm dextrans) exhibited high exposure in both 
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dLN exposure and skin (10-20-fold and 5-10-fold relative to 5 nm dextran, respectively), 
and particles of all tested sizes (25-500 nm polystyrene tracers) displayed low dLN 
exposure at levels similar to those seen with 5 nm dextran but 7-10-fold higher levels of 
skin exposure (Figure 4.5D). 
 
Figure 4.5 Tracer exposure within dLN and skin is size and form dependent. AUC 
of measured concentration profiles from 0 to 72 hr p.i. in (A) skin and (B) dLN. (C) 
Tissue exposure for size-matched dextran (red) and polystyrene spheres (blue) as 
percentage of total for both forms for the skin (left) and dLN (right). (D) AUC of 
tracers in skin and dLN. * indicates significant for 5-12 vs 25, 50, and 500 nm 
tracers by by one-way ANOVA and post-hoc Fisher's LSD tests, † indicates 
significance for 30 vs 25 and 56 vs 50 nm tracers by Mann-Whitney U tests. 
4.4 Discussion 
Biomaterials-based formulation strategies offer numerous advantages for the 
maximization of immunotherapeutic drug bioavailability in target tissues[92, 132, 134, 
139] while simultaneously limiting off-target effects.[139, 146, 147] Design criteria for 
increasing the efficiency and selectivity of agent delivery or retention in order to prolong 
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drug exposure in skin and dLN, tissue targets in a variety of immunotherapeutic regimens 
(e.g., intralymphatic immunotherapy[95, 96] as well as intradermal (or intralesional) 
injection for allergic contact dermatitis and plaque psoriasis[97] or oncolytic virus 
therapy in melanoma,[98] respectfully), using biomaterials thus has the potential to 
increase treatment efficacy, reduce off-target effects, and potentially eliminate the need 
for repeated local injections.[158-160]  
In this study, we explored the effects of macromolecular versus particulate size on 
profiles of skin retention and selectivity of dLN accumulation. A range of fluorescent 
tracer sizes relevant to engineered macromolecular and particulate drug carriers was 
implemented and the time points of analysis (24 and 72 hr p.i.) were chosen to allow the 
interrogation of both lymphatic transport mechanisms: cell-mediated uptake and 
migration which peaks 2-4 d p.i.[100, 161] versus passive lymphatic drainage from the 
interstitial injection site.[48, 58, 70, 71, 162] Corroborating earlier reports,[62, 163] we 
find retention within the injected skin to be size-dependent (Figure 4.3A), as is the 
relative selectivity of skin exposure to injected agent relative to systemic tissues (Figure 
4.3B). When size matched, macromolecular and particulate retention in the skin is 
equivalent (Figure 4.3A), resulting in similar, although somewhat higher in the case of 
~25-30 nm sized tracers, skin exposure (Figure 4.5C). Levels of dLN accumulation were 
higher for dextrans relative to polystyrene spheres at all tested sizes, save 5 nm dextran 
(Figure 4.4A). However, the specificity of dLN accumulation relative to systemic tissues 
was highest for an intermediate-sized (30 nm) dextran and at 72 hr p.i. for the largest 
(500 nm) polystyrene sphere tested (Figure 4.4C), presumably due to these tracers 
exhibiting the most robust levels of lymphatic uptake[101] versus high level of retention 
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within (Figure 4.3A) and restriction to (Figure 4.3B) the skin as well as dependency of 
the 500 nm tracer on cell-mediated transport to dLN (Figure 4.4B). Furthermore, 
macromolecular tracers accumulated in dLN at levels roughly ten times that of size-
matched polystyrene spheres (Figure 4.5B-D). Therefore, the interplay among 
hydrodynamic size and flexible, chain-like macromolecular versus rigid, spherical 
particulate form control the exposure at the site of skin injection versus simultaneous 
capacity to deliver payload to dLN, respectively. As previous studies[48, 144] have 
demonstrated that the extent of LN delivery influences immunotherapeutic outcomes,[48, 
144] we show herein the importance of considering the coupled effects of both the size 
and form/flexibility of biomaterial carriers to potentially increase therapeutic efficacy in 
vaccine or immunotherapy applications. 
Since after cellular uptake, drug carriers and their payload are presumably 
restricted to within migrating cells,[164] the mechanism of lymphatic-mediated delivery 
to dLN influences the signaling capacity of and the availability of intra- versus 
extracellular drug targets in migrating versus LN-resident cells to delivered payload.[92] 
Our results suggest that since dextran tracer concentrations in the dLN did not increase 
from 24 to 72 hr p.i. (Figure 4.4A, B), macromolecular transport from the skin to the dLN 
is primarily mediated via passive lymphatic drainage and is thus largely extracellularly 
available. Despite much lower total levels of dLN accumulation relative to tested 
dextrans, the same likely also holds for 25 nm polystyrene spheres (Figure 4.4B). 
However, the 50 and 500 nm polystyrene tracers exhibited an increase of approximately 
5- and 40-fold, respectively, by 72 hr p.i. (Figure 4.4B), and are thus, in part, restricted 
within dLN to the cells that migrated there from the periphery. These results corroborate 
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previous work demonstrating that accumulation of large (500 and 1000 nm) particles 
within dLN is cell-mediated and absent in dendritic cell-depleted mice[92] or in mice 
lacking dermal lymphatics,[71, 165] whereas smaller (20 nm) particles are still able to 
drain in dendritic cell-depleted mice and be taken up by a variety of dLN-resident 
cells.[92] Together, these results demonstrate that both the size and form of biomaterial 
drug carriers may impact levels and intra- versus extracellular locality of payload within 
dLN.  
Our results demonstrate the unexplored importance of carrier form for dermal and 
LN targeting applications as we noted a divergence between the size-dependency of 
macromolecule and rigid particle profiles of bioavailability within the skin and dLN. 
Most noteworthy, over 2% of the injected 30 nm dextran accumulated within the dLN, 
while dLN accumulation was only 0.2% of the injected amount for similarly sized 25 nm 
polystyrene spheres. We hypothesize these differences manifest as a result of the 
increased flexibility of chain-like macromolecular dextrans relative to that of rigid 
polystyrene spheres,[166-168] as differences in flexibility have been shown to influence 
both diffusion within skin[169] and lymphatic uptake.[101] How biomaterial rigidity and 
deformability influence the distribution of drug carriers throughout dLN as well as 
resulting profiles of resident cell uptake has yet to be fully elaborated. Also, whether 
particles with lower rigidities, such as those comprised of engineered biomaterials[170] 
rather than polystyrene, or particles with non-spherical shapes, such as rods or discs[171, 
172], exhibit size-dependent biodistribution profiles more similar to macromolecules or 
polystyrene spheres remains to be determined. Lastly, whereas the primary focus of this 
work was to elucidate the influence of hydrodynamic size and form on skin retention and 
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dLN accumulation, the coupled effects of numerous other characteristics of engineered 
biomaterial-based drug carriers (charge, shape, lipophilicity, matrix affinity, etc.) likely 
play a significant role as well and have yet to be systematically analyzed for dermal 
retention and dLN accumulation. 
4.5 Conclusion 
In summary, our results demonstrate that macromolecule and particle retention 
within the skin as well as accumulation and enrichment in dLN relative to systemic 
tissues is acutely influenced by hydrodynamic size but in different respects. The 
maximization of immunotherapeutic drug therapeutic efficacy within the skin and/or dLN 
as well as simultaneous limiting off-target effects may thus be tailored by changing the 
size and/or form of engineered biomaterial-based carriers. These results will inform the 




CHAPTER 5. VEGF-A and -C-induced Disease Progression Effects 
on Size-Regulated Profiles of Tumor-derived Molecular Association 
with Immune Cells within Locoregional Lymph Nodes Versus 
Systemic Tissues 
5.1 Introduction 
While early stage melanoma can be treated through surgery, advanced stage 
disease, which usually presents with tumor-induced immune suppression and metastasis, 
results in poor patient prognosis given our currently limited knowledge of treating the 
disseminated effects of cancer. Cancer immunotherapy is emerging as a successful 
treatment approach that induces durable objective responses in patients with advanced 
melanoma, yet these responses are achieved in only a quarter to a third of patients [173, 
174]. As tumor immune suppression involves multiple signaling pathways and several 
immune cell subtypes, including T cells, B cells, dendritic cells, and macrophages [175], 
it is difficult to target all the disseminated effects even with combination therapy [176], 
indicating a need for better understanding the pathways of crosstalk involved in cancer 
signaling to prevent disease progression. 
A compounding factor in tumor immune suppression is that the effects are not 
limited to the primary tumor microenvironment. By virtue of lymphatic drainage 
mechanisms, pathways of tumor immune suppression have the potential to be active in 
both the tumor microenvironment as well as sentinel lymph nodes. These draining lymph 
nodes (dLN) are continuously receiving incoming extracellular vesicles, endogenous 
signaling molecules, and antigens, which are thought to be partitioned primarily by 
molecular weight within the healthy lymph node by either entering the conduit system 
[16, 17] or passing through the subcapsular sinus barrier [16, 177] after which they may 
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mediate signaling with resident lymphocytes in deeper areas of the lymph node. 
Alternatively, larger soluble molecules may be transported by flow around the lymph 
node sinuses, through downstream lymphatics, and into venous blood circulation. While 
the return of excess fluid is necessary to maintain tissue fluid balance and homeostasis, 
there is also the opportunity for the eventual dissemination of lymph-borne molecules to 
systemic tissues such as the spleen, lungs, liver, and kidneys. Moreover, the presence of 
tumor-derived factors have been observed in patient sera, including a variety of proteases, 
growth factors, and immunosuppressive cytokines [42, 178], which indicate the potential 
for tumor-secreted molecules to influence immune cell functions [11] and pre-metastatic 
niche development [37, 46] within disseminated tissues.  
We have previously demonstrated that tumor progression modulates the size-
dependent tissue-level distribution of tumor-derived factors [62]; however, the specific 
influence of tumor blood and lymphatic vascular remodeling on the capacity of tumor-
secreted soluble factors (TSF - e.g. proteins, exosomes, and microvesicles) active in the 
regulation of immune signaling to distribute amongst subpopulations of systemic tissue-
resident immune cells versus dLN-resident cells that exhibit distinct lymph node 
substructural distributions as well as immunological functions remains unexplored. We 
therefore sought to evaluate the effects of tumor vascular remodeling, including those 
resulting from tumor VEGF-C overexpression (OE) and VEGF receptor-2 inhibition, on 
exposure of sentinel lymph node-resident as well as systemic tissue-resident phagocytic 
and immune cell subpopulations to factors derived from the tumor microenvironment. To 
accomplish this goal, we examined the in vivo biodistribution and uptake by immune cell 
subtypes of a panel of fluorescently labeled macromolecular and particulate tracers size-
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matched to physiological biomolecules ranging from 10-500 nm in hydrodynamic 
diameter after intradermal or intratumoral infusion in C57Bl6 mice in a temporal- and 
tissue-resolved fashion. Our results indicate that both VEGF-C OE and VEGFR-2 
inhibition partially restore molecular transport to dLN while reducing systemic tissue 
accumulation of species >30 nm. Furthermore, tumor-induced changes in dendritic cell 
and macrophage organization may underlie the altered accumulation of 30 and 10 nm 
TSF within tumor-dLN that resulted in decreased TSF exposure to barrier, migratory, and 
dendritic cells, but not to T and B cells in tumor-dLN. Our findings have important 
implications in the role of tumor blood and lymphatic remodeling in the immunological 
crosstalk between tumors, their draining lymph nodes, and systemic tissues that may be 
targets for metastasis as well as in the development of drug delivery strategies to mitigate 
the deleterious disseminated effects of advanced cancers. 
5.2 Materials and Methods 
5.2.1 Animal Tumor Models and Inhibitor Treatment 
C57Bl6 mice were purchased at 6 weeks of age from The Jackson Laboratory 
(Bar Harbor, Maine, USA). All protocols were approved by the Institutional Animal Care 
and Use Committee. For cohorts termed WT and VC, 0.5x10
6
 B16F10 or B16F10-VC 
murine melanoma cells were intradermally implanted into the left dorsal skin of 6-8 
weeks old mice on day 0, respectively. For cohorts termed R2, from day 2 post B16F10 
tumor implantation until endpoint, vandetanib at 50 mg/kg in 1% Tween 80 (Sigma-
Aldrich, St. Louis, MO, USA) or vehicle alone was administered daily by oral gavage 
using a 22 gauge reusable small animal feeding needle (Cadence Science, Staunton, VA, 
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USA). Tumor dimensions were measured with calipers and reported as an ellipsoidal 
volume. 
5.2.2 ELISA Measurements of Tissue VEGF-A and VEGF-C 
Tumor and skin tissues were dissected directly into Dulbecco's phosphate-
buffered saline (D-PBS) (VWR International Inc, West Chester, PA, USA) containing 
tubes and homogenized with 1.4 mm acid washed zirconium grinding beads (OPS 
Diagnostics LLC., Lebanon, NJ, USA) using a FastPrep-24 Automated Homogenizer 
(MP Biomedicals, Santa Ana, CA, USA). Homogenized samples were stored at -80°C 
until analyses. 1:10 dilutions of thoroughly mixed tissue homogenates in reagent buffer 
were measured for VEGF-A and VEGF-C by ELISA (R&D Systems Inc., Minneapolis, 
MN, USA) per the manufacturer’s protocol. 
5.2.3 Micro-computed Tomography Imaging for Vascular Measurements 
Animals were perfused with saline followed by neutral buffered formalin 
(Thermo Fisher Scientific) for 10 minutes, then with saline to rinse, and lastly MicroFil 
(Flow Tech Inc., Carver, MA) catalyzed at a viscosity appropriate for small vessels (5 
mL lead-based contrast agent: 2.5 mL diluent: 0.25 mL curing agent). Afterwards, 
perfused mice were carefully stored at 4°C overnight to cure the contrast agent. The 
following day, skin or tumor samples were harvested and stored in D-PBS. Micro-
computed tomographic imaging was accomplished using a SCANCO Medical µCT50 
(SCANCO USA, Inc., Wayne, PA, USA). µCT image slices were constrained using 
manual selection of the sample outline and processed with a Gaussian filter at a 
consistent global threshold via the SCANCO Medical µCT Evaluation Program before 3-
dimensional reconstruction [99]. 
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5.2.4 Fluorescent Tracers 
500 nm yellow-green and red fluorescent (505/515 and 580/605 
excitation/emission, respectively) carboxylate-modified microspheres were purchased 
from Thermo Fisher Scientific Inc. 40,000 Da (Dalton) Tetramethylrhodamine 
isothiocyanate (TRITC) dextran was purchased from Sigma-Aldrich. 500,000 Da amino-
dextran (Thermo Fisher Scientific Inc.) was covalently labeled by incubation with Alexa 
Fluor 647- or 700-NHS-Ester dyes (Thermo Fisher Scientific Inc.) in 0.1 M NaHCO3 at 
pH 8.4 for 4 hours on a tube rocker. AF647 and AF700 dextran-dye conjugates were 
purified from unreacted free dye by Sepharose CL-6B gravity column chromatography 
after conjugation. Purified dextran-fluorophore conjugates were further confirmed free of 
unconjugated dye by a second Sepharose CL-6B column analysis [62]. All reagents were 
used and maintained under sterile conditions. Hydrodynamic sizes were confirmed pre-
injection by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments, 
Ltd., Malvern, U.K.). 
5.2.5 Tracer Injections 
Fluorescent tracers suspended in saline were co-infused by syringe pump at a rate 
of ~300 nL per second directly into the center of tumors (groups WT, VC, and R2) using 
a 27 gauge needle while mice were under anesthesia via isoflurane. Alternatively, tracers 
were infused into the dermal layer of the skin of naïve mice (group termed N). For 
biodistribution experiments 500 nm red or yellow-green fluorescent microspheres (19 
pM), 30 nm AF700 or AF647 dextran (4.8 µM), and 10 nm TRITC dextran (4.8 µM) 
were co-infused in 10 µl of saline total. Mice were euthanized via CO2 asphyxiation at 
the prescribed times post tracer injection for each experiment. 
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5.2.6 Tracer Biodistribution Analyses 
At 4, 24, and 72 hr post tracer injection, mice were sacrificed and the tumor or 
skin injection site, tumor-draining axillary and brachial lymph nodes, spleen, lungs, liver, 
and kidneys were harvested and homogenized in D-PBS using 1.4 mm acid washed 
zirconium grinding beads with a FastPrep-24 Automated Homogenizer. Whole tissue 
homogenate fluorescence was measured with a Syngergy H4 BioTek plate reader 
(BioTek Instruments Inc, Winooski, VT, USA), compensation was applied, and 
fluorescent tracer amounts and concentrations were calculated from standard curves made 
by spiking individual naïve tissue homogenates with tracer solution.   
5.2.7 Tumor and Lymph Node Immunohistochemistry and Imaging 
Tumor, skin, and draining lymph nodes were frozen in optimum cutting 
temperature compound (Sakura Finetek USA, Inc., Torrance, CA, USA) in 2-
methylbutane (Sigma-Aldrich) chilled by liquid nitrogen and frozen tissue blocks were 
immediately stored at -20°C. For imaging of tracer draining lymph nodes, coverslips 
were mounted onto lymph node tissue slices (10 µm thickness) using Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA, USA) with no prior wash steps 
and within 30 minutes of imaging. Otherwise, lymph node, skin, and tumor tissue 
sections were fixed with pre-chilled acetone for 10 minutes at 4°C and subjected to 
standard immunofluorescence protocols using the following antibodies, which were 
obtained from Thermo Fisher Inc unless otherwise specified: FITC conjugated rat anti-
mouse CD31 (1:50), rabbit anti-mouse Lyve-1 (1:250), Alexa Fluor 633 goat anti-rabbit 
(1:300), Armenian hamster anti-mouse CD3e (1:50), Alexa Fluor 647 goat anti-hamster 
(1:300, Abcam plc., Cambridge, MA, USA), Alexa Fluor 488 conjugated rat anti-mouse 
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CD169 (1:100, BioLegend Inc, San Diego, CA, USA), biotinylated rat anti-mouse F4/80 
(1:200, Life Technologies), streptavidin-Alexa Fluor 555 (1:400, Life Technologies), 
biotinylated rat anti-mouse B220 (1:250), and Alexa Fluor 488 conjugated Armenian 
hamster anti-mouse CD11c (1:50, BioLegend Inc). Blocking and antibody dilutions were 
performed with 10% donkey serum (Sigma-Aldrich) in D-PBS. Slides were washed with 
0.1% Tween 20 (Sigma-Aldrich) in D-PBS for washing steps, counter stained with DAPI 
(VWR International Inc), and imaged using a 710 NLO confocal microscope (Carl Zeiss 
Microscopy Ltd, Jena, Germany) with a 20x magnification objective. 
5.2.8 Tracer Flow Cytometry Analyses 
Axillary and brachial draining lymph nodes were pooled and incubated with 1 
mg/ml Collagenase D (Sigma-Aldrich) in D-PBS with calcium and magnesium for 1 hr at 
37°C, passed through a 70 micron cell strainer (Greiner Bio-One, Monroe, NC, USA), 
washed, and resuspended in a 96 well plate (VWR International Inc) for staining.  Lung 
tissues were treated with the same procedure as lymph nodes. Spleen capsules were 
disrupted using needles and the cell suspension was passed through a 70 micron cell 
strainer, pelleted then incubated with red blood cell lysis buffer (Sigma-Aldrich) for 5 
minutes at room temperature, diluted with D-PBS, washed, and resuspended. Liver 
tissues were disrupted with needles then passed through a 70 micron cell strainer, 
centrifuged at 60xg for 1 minute to remove large debris and the supernatant was collected 
into a different tube and centrifuged at 300xg for 5 minutes. The pellet was resuspended, 
layered onto lymphocyte separation medium (Thermo Fisher Scientific Inc), and 
centrifuged for 20 minutes at 400xg. The mononuclear cell layer was recovered, 
incubated with red blood cell lysis buffer as before, washed, and resuspended for 
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staining. All antibodies for flow cytometry were from BioLegend, Inc. unless otherwise 
stated. Cells were blocked with 2.4G2 (Tonbo Biosciences, San Diego, CA, USA) for 15 
minutes on ice, washed, then stained with a fixable viability dye eFluor 455UV (1:1000, 
eBioscience, San Diego, CA, USA) for 15 minutes on ice before quenching with 0.1% 
bovine serum albumin in D-PBS (flow cytometry buffer). Antibodies were prepared in 
flow cytometry buffer at the following dilutions based upon preliminary titrations: PerCP 
anti-mouse CD45 (0.5:100), PE-Cy7 anti-mouse CD11b (0.625:100), BV421 anti-mouse 
CD11c (5:100), BV605 anti-mouse CD169 (5:100), BV650 anti-mouse B220 (2:100), 
BV711 anti-mouse CD3 (1.25:100), BV785 anti-mouse F4/80 (2.5:100). Cells were fixed 
with 4% paraformaldehyde (VWR International Inc) and kept at 4°C until analyzed with 
a customized BD LSRFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ, 
USA). Compensation was performed with AbC compensation beads (Thermo Fisher 
Scientific Inc) and data was analyzed using FlowJo software v10 (FlowJo, LLC, Ashland, 
OR).   
5.2.9 Tracer Diffusion Analyses 
Capillary tubes were loaded with 5.6 mg/ml rat tail collagen type I solution 
(Corning Inc., Corning, New York, USA) in D-PBS and allowed to gel overnight at 
37°C. 500 nm yellow green spheres, FITC conjugated 30 nm dextran, and TRITC 10 nm 
dextran were loaded in separate tubes and fluorescence imaging was performed every 4 
minutes for 2 hours at 37°C with a Zeiss AxioObserver Z1 inverted microscope (Carl 
Zeiss) with a 4x magnification objective. Image analysis was performed using ImageJ 
software. 
5.2.10 Statistical Analysis 
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Data are represented as the mean accompanied by S.E.M. and statistics were 
calculated using Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). 
Statistical significance was defined as p < 0.05 following two-way ANOVA and post-hoc 
analysis with Tukey tests or one-way ANOVA followed by Fisher’s Least Significant 
Difference (LSD) test. One, two, and three symbols denoting statistical significance 
represent p<0.05, 0.01, and 0.001 respectively, unless otherwise specified. Area under the 
curve (AUC) was calculated using the built-in Prism analysis tool. 
5.3 Results 
5.3.1 Endogenous and Induced or Suppressed Angiogenic and Lymphangiogenic 
Signaling During Melanoma Progression 
The dynamic changes within the blood and lymphatic vasculature of B16F10 
melanomas developing in the dorsolateral dermis of immune-competent C57Bl6 mice 
(Figure 5.1A) were assessed. First, VEGF-A concentrations within developing wildtype, 
untreated B16F10 melanomas (WT) were found to be increased with tumor growth 
(Figure 5.1B), changes that were reflected in a dramatic increase in tumor vascularity 
(Figure 5.1C, D). Conversely, VEGF-C concentrations within melanomas decreased with 
tumor growth (Figure 5.1B) and were accompanied by decreased lymphatic vessel 
densities (Figure 5.1B, bottom).  
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Figure 5.1 Characterization of tumor models. B16F10 (A, top), B16F10-VC (A, 
middle), and vandetanib treated B16F10 melanoma tumor growth curves (A, 
bottom). Tissue VEGF-A and VEGF-C concentrations of B16F10 tumors over the 
course of tumor progression (B, top), comparison to B16F10-VC and vandetanib 
treated tumors at Day 7 post implant (B, middle), and blood and lymphatic vessel 
densities quantified from immunohistochemistry (B, bottom). 3D reconstructions of 
micro-computed tomography of the tumor blood vasculature at Day 7 post 
implantation for B16F10 (C, top), B16F10-VC (C, middle), and vandetanib treated 
B16F10 (C, bottom); scale bars = 1 mm.  Representative immunohistochemistry 
images for tumor slices with arrows denoting blood vessel structures and 
arrowheads for lymphatic vessel structures; scale bars = 200 microns (D). * 
indicates significance by multiple t-tests. (A) n =4-12; (B-D) n = 3-5 mice per group. 
To mitigate the effects of endogenous vascular remodeling that accompany tumor 
growth and progression, two models of experimentally induced alterations in tumor 
vascular remodeling were established and characterized: B16F10 melanomas 
overexpressing VEGF-C (VC) (Figure 5.2A) and wildtype B16F10 melanomas grown in 
mice treated with a VEGFR-2 inhibitor vandetanib (R2). Rates of tumor growth were 
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similar between WT and VC tumor models, whereas R2 tumors resulted in significantly 
reduced tumor volumes from days 7-10 post implantation in comparison to vehicle 
control treated tumors (Figure 5.1A). As a result of VEGF-C o/e, VEGF-C levels in VC 
tumors were significantly elevated, ~five-fold (Figure 5.1B), and increased the 
peritumoral lymphatic density (Figure 5.1D). R2 tumors exhibited significantly reduced 
intratumoral VEGF-A levels, ~50% compared to WT melanomas (Figure 5.1B), an effect 
reflected in the dramatically reduced level of R2 tumor vascularity (Figure 5.1C, D). Both 
VC and R2 tumors, respectively, exhibited normalized (on par with naïve skin, Figure 
5.2B) VEGF-A concentrations and vascular densities versus VEGF-C concentrations and 
lymphatic densities (Figure 1B-D). 
 
Figure 5.2 VEGF-C Overexpression in Culture and Skin Section IHC. VEGF-C 
measurements for B16F10-VC compared to B16F10 in culture per 1,000 cells plated 
(A). ** indicates p<0.01 by two-way ANOVA and post-hoc Tukey’s test; n=2. IHC 
image of naïve skin section; scale bar = 250 microns (B). 
5.3.2 Clearance from Tumors is Increased with VEGF-C Overexpression and VEGFR-
2 Inhibition 
In order to evaluate the effects of tumor growth and experimentally induced 
alterations in (lymph)angiogenic signaling and remodeling on tumor-derived soluble 
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factor clearance from the tumor microenvironment, B16F10 tumors were implanted and 
mice received an intratumoral co-infusion of 500, 30, and 10 nm fluorescent tracers upon 
reaching day seven post tumor implantation, and were sacrificed at 4, 24, or 72 hours 
post-tracer injection (Figure 5.3A). 500 nm polystyrene spheres rely on cell-mediated 
transport as they are too large to be removed from the tissue interstitium site of injection 
by fluid transport alone due to extracellular matrix constraints [162]. 500 nm tracer 
distribution levels were thus used to evaluate the impact of endogenous and induced or 
suppressed angiogenic and lymphangiogenic signaling during melanoma progression on 
cell-mediated transport from the tumor.  We next utilized dLN cellular association with 
30 and 10 nm tracers to assess soluble lymphatic transport of tumor-derived molecules 
under the effects of altered angiogenic and lymphangiogenic signaling during melanoma 
progression.  
As previously reported [62, 163, 179], retention within the skin site of injection is 
acutely size-dependent (Figure 5.3B) and is slowed by WT tumor growth (Figure 5.3C). 
30 and 10 nm tracers were retained at reduced levels in VC and R2 tumors (Figure 5.3C). 
500 nm tracer retention in R2 but not VC tumors was also restored to levels seen in N 
tissues (Figure 5.3C). These results suggest VEGF–A- and -C-dependent effects on tumor 




Figure 5.3 VC and R2 Partially Recover 500 and 10 nm LN Drainage, while VC 
Prevents Enhanced 500 and 30 nm Tracer Systemic Dissemination. Timeline and 
group descriptions for tumor implantations with endpoint analyses at 4, 24, and 72 
hr post intratumoral tracer injections (A). Percent of injected tracer remaining at 
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the dermal injection site in naïve (non-tumor implanted) mice representing size-
dependent tracer clearance in healthy animals (B). Tracer exposure within the skin 
or intratumoral site of injection expressed as AUC of the 0-72 hours post-injection 
time series (C). Time-resolved tracer accumulation within dLN (D-F) and total 
exposure from 0-72 hrs (G-I). Systemic tissue tracer levels combined for spleen, 
lungs, liver, and kidneys (J-L) and associated total exposure from 0-72 hrs (M-O). 
Ratio of accumulating tracer concentrations within dLN vs systemic tissues (P-R). 
(D-F; J-L; M-O) * indicates significance by one-way ANOVA; (G-I; M-O) * 
indicates significance by multiple t-tests; n = 4-9 mice per group. 
5.3.3 VEGFR-2 Inhibition Partially Recovers 500 and 10 nm Tracer dLN 
Accumulation, while VEGF-C Overexpression Results in Reduced Systemic Tissue 
Exposure to 500 and 30 nm Tracers 
We next investigated the effects of altered (lymph)angiogenic signaling in the 
dissemination of tumor-derived molecules by measuring extratumoral tracer 
accumulation within the local dLN versus systemic tissues (spleen, lung, liver, and 
kidneys) in tumor-bearing mice. After injection, 500 and 10 nm tracers exhibited a 
significant reduction in accumulation profiles within dLN at 72 hours p.i. as compared to 
injections in the dermis of naïve mice, but for the 30 nm tracer only a modest reduction in 
dLN accumulation was observed at each measured time point (Figure 5.3D-F). VC and 
R2 tumors also demonstrated increased 500 nm exposure within dLN relative to WT 
tumor levels, approaching that of naïve animals (Figure 5.3G). This trend for increased 
dLN exposure for the VC and R2 groups over the WT melanomas was similarly observed 
for the 10 nm, but not for the 30 nm, tracer (Figure 5.3H-I). When examining systemic 
biodistribution profiles, 500 and 30 nm tracer accumulation within systemic tissues was 
increased for WT over naïve injected tissues as we have previously reported [62, 179], 
whereas, conversely, systemic accumulation of 10 nm tracer was significantly greater for 
naïve and R2 groups than WT tumors at 24 hours p.i. (Figure 5.3J-L). When considering 
500 nm tracer exposure in systemic tissues, VC but not R2 tumors exhibited profiles 
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significantly diminished relative to WT tumors and more similar to that of N tissues 
(Figure 5.3M). Exposure of 30 nm tracer in systemic tissues on the other hand was 
reduced in VC tumors relative to WT tumors, which was unchanged relative to N tissues 
(Figure 5.3N). Conversely, systemic exposure to 10 nm dextran exposure was reduced in 
WT tumors relative to N tissues, an effect reversed in R2 but not VC tumors (Figure 
5.3O). As a result of these altered profiles of dissemination and when considering the 
volume of the tissue in which the tracers are distributed to determine an average tissue 
concentration, all tested tumor types reduced the relative enrichment of 500 and 10 nm 
tracer exposure within dLN relative to systemic tissues at late (72 hr) versus early (4 hr) 
times post injection (p.i.), respectively (Figure 5.3P,R). 30 nm tracer on the other hand 
exhibited high levels of dLN enrichment relative to systemic tissues irrespective of time 
p.i. (Figure 5.3Q). These results indicate partially recovered lymphatic drainage and a 
reduction in systemic tissue over-exposure to tumor-derived factors resulting from tumor 
growth and experimentally induced alterations in tumor (lymph)angiogenic signaling. 
5.3.4 Hydrodynamic Size- and Tumor (Lymph)angiogenic Signaling-dependent Profiles 
of Tracer Association with Discrete Immune Cell Subpopulations within dLN 
Flow cytometry analysis confirmed detection of the 500 nm tracers primarily in 
CD11c, F4/80, and, to a lesser extent, B220 positive subsets (Figure 5.4A-B). When 
comparing between the N tissues to all tested tumor types, no significant differences in 
the frequency of 500 nm+ cells within cellular populations were observed (Figure 5.4B), 
yet higher total counts of 500 nm+ cells in VC dLN were measured (Figure 5.4C). This 
trend in accumulation within B220 positive cells - likely either B cells or plasmacytoid 
DCs - could be the result of an increased transfer of 500 nm tracer from migratory 
CD11c+ to dLN resident B220+ populations (Figure 5.4C). 
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Figure 5.4 Enhanced Cellular Tracer Exposure within VC and R2 dLN. Example 
flow cytometry gating of 500 nm tracers in N and WT dLN (A). Cell-mediated 
transport directs 500 nm tracer exposure calculated as AUC from 0-72 hr from the 
percent of each marker positive subpopulation (B) and from total cell counts (C). 
Lymph-soluble 30 and 10 nm tracer flow cytometry gating (D) and juxtaposition of 
exposure calculated similarly as percent of each marker positive subpopulation (E) 
and from total cell counts (F). * indicates significance by one-way ANOVA; n = 4-6 
mice per group.  
 Uptake of lymph-soluble tracers by dLN-resident cells was next analyzed by flow 
cytometry (Figure 5.4D). Compared to naïve dLN, the frequency of 30 and 10 nm tracer 
positive CD11c+ and F4/80+ cells was reduced for WT dLN, an effect partially restored 
in R2 but not VC tumors (Figure 5.4E). Strikingly, in distinct contrast to 30 nm tracer 
that exhibited minimal to no association with B220+ and CD3+ cell populations, 10 nm 
tracer was taken up appreciably by both B220+ and CD3+ cells in N animals, levels that 
were reduced by WT tumors but restored in R2 tumors (Figure 5.4E). However, when 
considering the total number of tracer+ cells, many of the differences observed in the %+ 
analyses were not observed, yet the overall count of 10 nm+ B220+ cells in VC was 
greater than WT dLN potentially indicating the ability of small molecules to distribute 
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amongst a hyperplastic cellular population [18, 180] for increased exposure following 
lymphatic drainage (Figure 5.4F).   
5.3.5 dLN Distributions of Tracers and Resident Cell Subpopulations are Influenced by 
Hydrodynamic Size-dependent Tumor Vascular Remodeling, Respectively 
Confocal imaging and analysis of tissue sections of tracer dLN demonstrated 
restriction of 30 nm dextran within the subcapsular sinus of N dLN while the 10 nm 
tracer penetrated deeper into the cortical areas and was more broadly distributed (Figure 
5.5A). Contrastingly, 500 nm polystyrene spheres resulted in punctate, tracer positive 
areas within the paracortex of dLN at 72 hr, but not 4 hr, p.i. (Figure 5.5B). 500 nm 
tracers exhibited the farthest penetration at 72 hours p.i. while 10 nm tracers exhibited a 
moderate level of subcapsular infiltration at both time points (Figure 5.5A-B). The 30 nm 
tracers were restricted within close proximity to the capsule at 4 and 72 hr p.i. indicating 
accumulation within the subcapsular sinus and potentially dLN-resident barrier cells 
(Figure 5.5C). Immunohistochemistry images demonstrated cell subpopulation 
compartmentalization in the interior versus outer, capsule-adjacent regions of dLN of 
CD3+ and CD11c+ versus B220+, CD169+, and F4/80+ cells, respectively (Figure 5.5C), 
which suggests that tracers with differing dLN distribution profiles likely accumulate 
within different resident cell subpopulations.  
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Figure 5.5 Tracer Localization, Cellular Frequencies, and Organizational 
Remodeling within dLN. Tracer drainage and localization within skin dLN at 4 (A) 
and 72 hr (B) p.i. in the naïve dermis. Total cell counts (D) and percentages for each 
marker subpopulation (E) within naïve and tumor-dLN. Scale bars = 200 microns; n 
= 4-6 sections from 2-3 separate LN per group (A-C); n = 4-6 mice per group (D-E). 
We next characterized whether (lymph)angiogenic signaling influenced dLN 
cellular organization and frequencies. For WT versus N dLN, B220+ and Lyve-1+ zones 
were enlarged, CD169+ barrier cells (which includes subcapsular sinus macrophages and 
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medullary sinus macrophages) were greatly disorganized, CD169+ cells were no longer 
restricted to the dLN periphery, and we noted an overall reduction in F4/80+ areas 
(Figure 5.5C). For VEGF-C overexpressing tumor-dLN, B220+ areas were increased 
from WT dLN, with CD169+ maintaining their location near the subcapsular sinus 
similar to that observed in naïve dLN (Figure 5.5C). Upon imaging VEGFR-2 inhibited 
tumor-dLN, we found increased B220+ areas with irregular patterns of localization and 
reduced CD169+ and F4/80+ areas resembling WT dLN (Figure 5.5C).  Total numbers of 
B220+ and CD3+ cells were elevated in WT relative to N tissues yet there was a 
reduction in CD3+ relative to B220+ frequency when quantified as a percent of the total 
dLN cells (Figure 5.5D, E). The total number of dLN B220+ and CD3+ cells were 
increased for VC, but reduced for R2 tissues as compared with WT (Figure 5.5D), yet 
only the R2 exhibited significant differences from WT dLN in B220+ and CD3+ 
percentages of total cells (Figure 5.5E). 
5.3.6 Overall Tissue Cellular Association with Tumor Progression Increased for 500 
nm, Especially in Spleen Cells, but Decreased for 10 nm Tracers  
When analyzing the frequency of each cell subpopulation with detectable levels of 
associated tracer in assayed tissues, we found 500 nm tracers were primarily associated 
with CD11c and F4/80 populations within naïve dLN and spleen, 30 nm tracers were 
more prevalent in splenic cell populations, and 10 nm tracers were distributed amongst 
both spleen and lung immune cells (Figure 5.6A-C).  
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Figure 5.6 Systemic Tracer Cellular Exposure. Counts for tracer positive cells 
expressing CD11c, F4/80, B220, or CD3 in local dLN and systemic tissues including 
spleen, lungs, and liver (A-C). Summation of maximum number of tracer positive 
cell counts within all tissues at either 4, 24, or 72 hr post tracer injection (D-F). 
Proportional tracer exposure represented as AUC of tracer positive cell counts from 
0-72 hr in disseminated tissues (G-J). * indicates significance by two-way ANOVA 
with post-hoc Tukey’s tests; n =4-6 mice per group. 
However, upon examining the number of tracer positive cells and comparing the 
maxima among the tumor groups, trends suggest an increased amount (summed for all 
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tissues analyzed) of CD11c, F4/80, B220, and CD3 populations are associated with 500 
nm tracers in WT, VC, and R2 animals (Figure 5.6D). The maximum number of 30 nm 
tracer positive cells in all tissues combined was relatively similar amongst all groups, 
with the exception that B220+ cellular exposure increased with VEGFR-2 inhibition 
(Figure 5.6E). 10 nm tracer maximum cell numbers were actually lower for WT as 
compared with naïve tissues for CD11c+ populations and trends suggest lower levels as 
well for organism-wide 10 nm positive F4/80+ and CD3+ cell counts (Figure 5.6F) which 
corroborates the previous tissue-level biodistribution data (Figure 5.3O). 
Analyzing the relative extent of tracer exposure as AUC of tracer positive cell 
numbers per each tissue, the exposure for all cell subtypes was decreased for dLN and 
increased for systemic tissues for the 500 nm, but not 30 or 10 nm tracers in WT versus 
naïve groups (Figure 5.6G-J). Meanwhile, 500 nm exposure to F4/80+, B220+, and 
CD3+ cells in the liver of naïve mice shifts towards the spleen in WT mice, but this trend 
is reversed with CD11c+ cells in WT liver receiving more of the total 500 nm tracer 
exposure, and is only partially recovered with VEGFR-2 inhibition (Figure 5.6G-J). 30 
nm exposure profiles remained relatively constant between naïve and WT groups, with 
only the B220+ population showing a shift in total exposure from the spleen to dLN for 
WT and VC groups versus N (Figure 5.6I), potentially due to greater numbers of B cells 
(Figure 5.5D). The lung and spleen received the majority of 10 nm tracer exposure in 
naïve mice, but increased dLN and liver exposure was observed for WT and VC groups 
(Figure 5.6G-H). Interestingly, VEGFR-2 inhibition seemed to skew CD11c+ and B220+ 
cell exposure towards the spleen for 500 nm tracer as compared to WT trends (Figure 
5.6G-J). 
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5.3.7 Altered 30 and 10 nm Tracer Exposure for Tumor-dLN Dendritic, Barrier, and 
Migratory Cellular Populations, but not B and T Cells, while 500 nm Exhibits 
Size-dependent Restriction of Diffusion by Cross-linked Collagen 
We further subdivided tracer association by cellular localization within dLN 
among paracortex cells (B cells (B), T cells (T), plasmacytoid dendritic cells (pDC), and 
conventional dendritic cells (cDC)), barrier cells (subcapsular sinus macrophages (SSM), 
medullary sinus macrophages (MSM), and medullary cord macrophages (MCM)), and 
migratory cells (dermal dendritic cells (dDC) and Langerhans’ cells (LC)). 30 and 10 nm 
TSF exposure to pDC and cDC paracortex cells was reduced in WT versus N dLN, while 
500 nm %+ exposure profiles were relatively unaffected by malignant status (Figure 
5.7A) confirming previous trends for the generalized marker+ cells (Figure 5.4B, E). 
SSM and MCM barrier macrophages showed reduced association with 30 and 10 nm 
tracers, respectively, in WT dLN, which were only partially restored in R2 but not VC 
models (Figure 5.7B). We also observed that 30 and 10 nm exposure was reduced in WT 
dLN migratory cells and that LC, but not dDC exposure profiles were moderately 
recovered with R2 but not VC conditions (Figure 5.7C).  
Soluble molecular transport within tissues, such as the tumor interstitium, may be 
hindered by the collagen matrix, thus altering TSF clearance and accumulation profiles 
independent of changes in vascular remodeling; hence, we measured TSF diffusion 
within collagen filled capillary tubes. All tubes were loaded evenly with tracer solutions 
at time zero (Figure 5.7D) and imaged every 4 minutes for 2 hours after which a size-
dependent separation was notable (Figure 5.7E). Measurements of the fluorescence 
intensity profiles within the collagen gel areas showed that the 10 nm dextran exhibited 
the quickest diffusion into the gel followed by the slightly hindered 30 nm dextran, while 
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the 500 nm polystyrene spheres experienced greatly hindered diffusion (Figure 5.7F). 
Curve fitting of intensity profiles showed that the time constant for 10 nm tracer was on 
the order of 10 minutes while the 30 nm tracer’s was approximately 60 minutes, both of 
which were significantly less than the ~6.5 hours calculated for the 500 nm tracer (Figure 
5.7G). Interestingly, this profile mirrored the average accumulation profiles within 
paracortex-resident B and T cells in dLN (Figure 5.7A) indicating a potential role for 
diffusion in TSF uptake by these cell types. 
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Figure 5.7 Size-dependent Tracer Distribution Profiles Among Paracortex, Barrier, 
and Migratory Cells and Tracer Diffusion through Collagen. Tracer exposure 
profiles within dLN were separated by location into paracortex (A), barrier (B), and 
migratory (C) cell groups. Fluorescent images of tracer diffusion in collagen filled 
capillary tubes at (D) time of individual tracer addition and (E) 120 minutes later. 
Normalized fluorescence intensity of diffusing tracer signal into the collagen gel (F). 
Diffusion time to half max derived from one phase non-linear fitting of diffusion 
profiles plotted against tracer hydrodynamic diameter (G). * indicates significance 
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by two-way ANOVA with post-hoc Tukey’s tests. n = 4-6 mice per group (A-C); n = 
3 experiments per group (D-G). 
5.4 Discussion 
Tracer biodistributions amongst immune cell subtypes reveal unexpected effects of 
altered angiogenic and lymphangiogenic signaling. VEGFR-2 inhibition was expected to 
normalize blood vessels and, therefore, tracer exposure to systemic tissues. While we 
observed systemic exposure profile AUCs return to near naïve levels for the 10 nm tracer 
(Figure 5.3O), VEGFR-2 inhibitor treatment also resulted in partially normalized 500 and 
10 nm dLN accumulation as compared to WT animals (Figure 5.3G, I) which may be 
attributed to normalized intratumoral fluid pressure [65, 101] and/or a partial reduction of 
tumor blood vessel pore sizes [66] creating opportunity for enhanced lymphatic transport. 
Contrarily, VEGF-C OE was expected to maximally influence 30 nm tracer profiles in 
dLN as this is the primary lymphatic draining molecule of the tracer panel [179]. 
However, we saw no significant change between WT and VC groups in 30 nm tracer 
exposure to dLN (Figure 5.3H), yet VEGF-C OE increased dLN AUC levels significantly 
for the 500 and 10 nm tracers in VC versus WT dLN (Figure 5.3G, I) indicating the 
potential for tumor lymphangiogenic remodeling to exert a greater effect on migratory 
cell populations or the transport of lymph-soluble 10 nm tracer, rather than larger 30 nm 
species. Combined, these findings demonstrate that inhibiting tumor angiogenic 
remodeling can impact TSF cell-mediated and soluble-lymphatic drainage of TSF, yet 
modulating tumor lymphangiogenic remodeling can influence systemic tissue exposure in 
a size-dependent manner.  
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 Previous studies of dLN responses to cancer have been primarily focused upon 
remodeling of cellular subsets, particularly lymphatic endothelial cells [20], stromal cells 
[19], and B cells [18], or reorganization of extracellular matrix structure and composition 
[18], yet the influence of tumor remodeling and endogenous or induced angiogenic and 
lymphangiogenic signaling on the partitioning of macromolecular and particulate species 
within these adapted dLN has been largely unexplored. It is known that molecular 
passage into the conduit system is usually restricted to molecules below 70 kDa, while 
larger molecular weight species entering the lymph node are filtered around the 
subcapsular sinus and even with Vaccinia virus-induced remodeling of the dLN, size-
based fluorescent tracer distribution do not change [16]. Additionally, subcapsular and 
medullary sinus macrophages have been observed to play an important barrier function in 
the capture and presentation of lymph-borne pathogens that would otherwise overwhelm 
the dLN [181]. In our current study, we noted a disruption in the F4/80+ CD169+ SSM 
layer surrounding WT and VEGFR-2 inhibitor treated LNs (Figure 5.5C) and our flow 
cytometry results demonstrated a significantly lower percentage of 30 nm tracer positive 
exposure for SSMs and 10 nm tracer exposure for MCMs in WT dLNs (Figure 5.7A, B). 
While the 30 nm dLN exposure profile is lower for WT animals (Figure 5.3H), our other 
metrics of flow cytometry and IHC suggest that this may be due to disorganization of 
SSM barrier cells in the remodeled tumor dLN that results in reduced uptake and 
accumulation of 30 nm tracer that may coincide with a reduction in tracer lymphatic 
transport. Also, 30 and 10 nm tracer exposures to LN paracortex-resident cDC, pDC, 
dDC, and LC are decreased (Figure 5.7C) in accord with reductions in tissue-level 
accumulation profiles (Figure 5.3H, I) in WT as compared to naïve dLN, yet T and B cell 
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exposure levels in WT versus naïve dLN are not significantly different (Figure 5.7A). 
These data indicate that tissue-level changes in transport to and molecular abundance 
within the dLN do not always translate to an equally proportional change in molecular 
association and/or uptake by all dLN cell subtypes, specifically for tumor dLN.   
 While the disseminated effects of tumor-derived molecules in systemic tissues are 
an emerging area of study, a recent report for an E.G7 mouse tumor model indicated that 
the immune suppressive effects due to tolerance induction by marginal zone monocytes 
on CD8+ T cells were absent in splenectomized mice [11]. Our results indicate that 
neither VEGF-C OE nor VEGFR-2 inhibition could mitigate the exposure of tracer 
molecules on spleen-resident cells (Figure 5.6G-J). However, VEGFR-2 inhibition in WT 
tumors did result in less 10 nm tumor-derived molecular exposure in lung-resident 
CD11c+ and F4/80+ cellular populations as compared to WT exposure (Figure 5.6G-H), 
which is a common site for melanoma metastases [55, 182]. While the use of angioplastic 
therapies may be desirable for reducing primary tumor growth, our results indicate 
changes in tumor-derived molecular exposure profiles and other examples demonstrating 
enhanced metastasis following angiogenic inhibition [49, 183] indicate the need to further 
assess adverse TSF signaling effects. 
5.5 Conclusions 
Through both tissue- and cellular-level analyses, our results inform that VEGF-C 
OE and VEGFR-2 inhibition reduce systemic tissue accumulation of 500 and 30 nm 
species while partially restoring molecular transport to dLN. Altered accumulation 
profiles of 30 and 10 nm TSF within tumor-dLN, specifically with decreased molecular 
exposure to dendritic, migratory, and barrier cell subsets, were accompanied by dendritic 
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cell and macrophage disorganization. Our findings have important implications in the 
role of tumor blood and lymphatic remodeling in modulating tumor immune suppression 
and metastasis, and for informing the development of therapeutic or preventive strategies 
against advanced cancer progression. 
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CHAPTER 6. CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
6.1 Contributions to the Field 
6.1.1 Multi-tool Integration to Determine In Situ Soluble Factor Clearance, 
Accumulation, and Biodistribution at Picomolar Levels 
This thesis dissertation work integrated concepts of lymphatic and vascular 
physiology with unique and state-of-the-art bioengineering tools to analyze the influence 
of cancer progression and vascular remodeling on SF transport and resulting profiles of 
tissue and cellular distribution. This strategy is fundamentally different from widely-used 
in vitro studies that merely analyze TSF production by the co-incubation of cells without 
any influence of clearance into the blood versus lymphatic vascular systems and 
distribution to disseminated tissues. Major advantages of the molecular tracer 
methodology include its cell-source unbiased basis, facile implementation for in situ 
tracing, high performance in terms of limit of detection, and format that allows for 
integration with other analytical platforms such as single-cell surface marker profiling 
and co-localized imaging studies. The extremely low limits of detection enable 
quantification of transport to and concentration within very small murine lymph nodes. 
For example, detection and quantification of endogenously produced SF are limited by 
significant dilutional effects as well as uncertainty in the spatial and temporal source of 
constitutive or inducible reporter systems. Furthermore, biodistribution analysis of 
specific exogenously labeled and supplied SF can be challenging due to degradation in 
vivo. To circumvent these limitations, a panel of near-infrared fluorescently labeled 
molecular tracers comprised of inert polymers that are resistant to hydrolysis and 
proteolytic degradation was established. Near infrared fluorophore selection was 
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performed to minimize tissue absorbance and light scattering as well as minimize 
fluorescence overlap to achieve simultaneous limits of detection in the picomolar range 
for multiple tracers, thus reducing the number of animals needed for analysis. Using an 
endpoint approach with plate reader detection also overcomes conventional live animal 
imaging methods where depth of tissue penetration, signal to noise ratio, and light 
scattering limit the sensitivity of detection.  
Since SF and therapeutic agents such as small molecule drugs and engineered 
drug delivery vehicles vary widely in hydrodynamic diameter and the rate and extent of 
blood versus lymphatic clearance from healthy tissues are acutely size-dependent [56, 
58], tracers over a range of 5-500 nm in hydrodynamic diameter were chosen to size 
match a range of physiological biomolecules. Thus, the designed methodology enables 
not only analysis of the effect of molecule size on clearance, but also distinguishes 
between blood versus lymphatic mediated SF clearance mechanisms. This approach 
provided broad insight into the pathophysiology of SF in cancer as well as provided 
design criteria for tumor and TDLN targeted therapeutic approaches and delivery design. 
6.1.2 Validating Conservation of Size-dependent Lymph Node Drug Targeting in 
Melanomas over the Course of Disease Progression 
In line with previous reports [101], the major lymph-draining tracers were found to 
be 30 nm in hydrodynamic size in both healthy (Figure 3.3D-E,G) and malignant (Figure 
3.7E) skin. Interestingly, despite reduced total levels of dLN accumulation, the relative 
accumulation of 30 nm tracer in dLN relative to systemic tissues remained relatively 
unchanged. This indicates that despite reductions in lymphatic transport function (Figure 
3.7), TSF approximately 30 nm in diameter such as exosomes and large protein 
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complexes continue to primarily signal extratumorally within TDLN (Figure 3.8C-D) as 
opposed to systemic tissues. These results also highlight the potential utility of drug 
formulations ~30 nm in size to accumulate substantially in sentinel lymph nodes when 
intralesionally administered which is an important discovery for immunotherapeutic drug 
delivery applications.  
6.1.3 Demonstrating Enhanced Systemic Tissue Accumulation of Tumor-derived 
Factors with Advanced Malignancy 
Herein the results show that 500 and 50 nm tracers cleared from the tumor 
accumulate at elevated levels in the liver and spleen (Figure 3.6D). Moreover, we found 
these tracers to accumulate appreciably within the lungs of animals with advanced (day 9 
post-implant) malignancies (Figure 3.6C), a redirection in their biodistribution that 
occurred concurrently with attenuated transport to TDLN (Figure 3.7). TSF signaling that 
would take place within dLN in naïve animals appears to instead be redirected to lungs of 
tumor-bearing animals.  
Small to intermediate size biomolecules secreted by tumors such as peptides, 
proteins, and other biomolecules have also been implicated in a multitude of roles that 
exacerbate disease progression [109, 113]. We provide evidence that exposure of small 
molecules ~5 nm in hydrodynamic size is also appreciably increased in systemic relative 
to dLN tissues in tumor-bearing animals (Figure 3.6). Overall, accumulation of 500, 50 
and 5 nm tracers shifted significantly from dLN to systemic tissues over the time course 
of disease progression evaluated here (Figure 3.8). As a result, profiles of TSF tracer 
accumulation in the liver and lung diverged from that seen in naïve animals and instead 
more closely mirrored those of the primary tumor (Figure 3.8D). This suggests that 
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signaling processes active within the tumor microenvironment have the potential to be 
operational in systemic tissues of melanoma-bearing animals and may significantly 
regulate and negatively influence the course of disease progression. They also indicate 
that therapeutic agents administered intralesionally, for example oncolytic 
immunotherapy, may also result in significant signaling activity outside of the primary 
tumor in distributed systemic tissues. 
6.1.4 Informing the Rational Design of Drug Targeting and Delivery Strategies to 
Achieve Locoregional Immunomodulation in Skin and dLN 
As previous studies[48, 144] have demonstrated that the extent of LN delivery 
influences immunotherapeutic outcomes,[48, 144] we show herein the importance of 
considering the coupled effects of both the size and form/flexibility of biomaterial 
carriers. While Fifis et al. [91] showed that the size of antigen conjugated polystyrene 
spheres influenced antibody titers, LN cellular uptake, and anti-tumor immune response, 
the study did not include a size-matched comparison versus any other carrier formulation. 
Similarly, the study by Manolova et al. [92] demonstrated the effect of particle size on 
cellular transport and lymphatic uptake, which included many sizes of polystyrene 
particles and one virus-like particle, but had no direct, size-matched comparison between 
formulation or flexibility (the virus-like particle was 30 nm in diameter while the 
adjacent particle sizes were 20 and 100 nm). Additionally, the effect of biomaterial form 
and flexibility has been studied with respect to improving carrier circulation [93] and 
uptake of particles by cells [94], but has not been previously explored as a variable 
influencing dermal retention or dLN accumulation. Therefore, the effect of different 
forms on size-matched biomaterial carrier performance for dermal retention and dLN 
delivery is a knowledge gap in the field that this dissertation addresses by using 
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comparisons between eight tracers (5, 10, 12, 30, and 54 nm dextran and 25, 50, and 500 
nm polystyrene spheres) within an order of magnitude of the known optimum 
hydrodynamic size range for lymphatic delivery with two size matched, direct 
comparisons between 500 kDa (30 nm) dextran and 25 nm polystyrene spheres as well as 
2000 kDa (54 nm) dextran and 50 nm polystyrene spheres. The time points of analysis 
(24 and 72 hr p.i.) were chosen to allow the interrogation of both lymphatic transport 
mechanisms: cell-mediated uptake and migration which peaks 2-4 d p.i.[100, 161] versus 
passive lymphatic drainage from the interstitial injection site [48, 58, 70, 71, 162].  
Corroborating earlier reports [163, 179], we find retention within the injected skin 
to be size-dependent (Figure 4.3A), as is the selectivity of skin exposure to injected agent 
relative to systemic tissues (Figure 4.3B). When size matched, macromolecular and 
particulate retention in the skin is equivalent (Figure 4.3A), resulting in similar, although 
somewhat higher in the case of ~25-30 nm sized tracers, skin exposure (Figure 4.5C). 
Levels of dLN accumulation were higher for dextrans relative to polystyrene spheres at 
all tested sizes, save 5 nm dextran (Figure 4.4A). However, the specificity of dLN 
accumulation relative to systemic tissues was highest for an intermediate-sized (30 nm) 
dextran and at 72 hr p.i. for the largest (500 nm) polystyrene sphere tested (Figure 4.4C), 
presumably due to these tracers exhibiting the most robust levels of lymphatic 
uptake[101] versus high level of retention within (Figure 4.3A) and restriction to (Figure 
4.3B) the skin as well as dependency of the 500 nm tracer on cell-mediated transport to 
dLN (Figure 4.4B). Furthermore, macromolecular tracers accumulated in dLN at levels 
roughly ten times that of size-matched polystyrene spheres (Figure 4.5B-D). Therefore, 
the interplay among hydrodynamic size and flexible, chain-like macromolecular versus 
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rigid, spherical particulate form control the exposure at the site of skin injection versus 
simultaneous capacity to deliver payload to dLN, respectively.  
6.1.5 Providing Insight of Molecular Mechanisms of Tumor Vascular Remodeling 
Influencing Soluble Factor Transport and Cellular Association 
Tracer biodistribution data in this dissertation work show interesting, yet 
unexpected trends for dLN versus systemic tissue accumulation profiles under the effects 
of altered angiogenic and lymphangiogenic signaling. VEGFR-2 inhibition was expected 
to normalize blood vessels and, therefore, tracer exposure to systemic tissues. While we 
observed systemic exposure profile AUCs return to near naïve levels for small molecules 
around 10 nm in hydrodynamic diameter, VEGFR-2 inhibitor treatment also resulted in 
partially normalized 500 and 10 nm dLN accumulation as compared to WT animals 
which may be attributed to normalized intratumoral fluid pressure and/or a partial 
reduction of tumor blood vessel pore sizes creating opportunity for enhanced lymphatic 
transport. Contrarily, VEGF-C OE was expected to maximally influence 30 nm tracer 
profiles in dLN as this is the primary lymphatic draining molecule of the tracer panel 
[179]. However, we saw no significant change between WT and VC groups in 30 nm 
tracer exposure to dLN, yet VEGF-C OE increased dLN exposure levels significantly for 
the 500 and 10 nm tracers in VC versus WT dLN indicating the potential for tumor 
lymphangiogenic remodeling to exert a greater effect on the lymphatic transport of cells 
and small 10 nm (40 kDa) molecules, rather than larger 30 nm (500 kDa) species. 
Combined, these findings demonstrate the inherent relationship between tissue 
angiogenic and lymphangiogenic signaling and the subsequent remodeling that impacts 
the blood clearance versus lymphatic drainage of interstitial molecules in a size-
dependent manner. 
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6.2 Future Directions 
6.2.1 Developing Therapeutic Strategies to Curtail the Aberrant Transport Profiles and 
Negative Disease Outcomes of Cancer Soluble Factors 
By better understanding the transport of tumor-derived molecules throughout the 
body and the effects of tumor vascular remodeling on such transport, this work informs a 
new avenue of therapy development against systemic signaling and progression of cancer 
by exposing the timing and tissue locations in which inhibitor or neutralizing therapies 
may have the greatest benefit. Increased understanding of endogenous tumor-secreted 
molecular profiles could also be used as prognostic indicators of cancer progression as 
we have observed increased accumulation of TSF in systemic tissues in association with 
increased vascular leakiness.  
Future studies could involve combining angioplastic and immunotherapy 
treatments with the knowledge gained from this dissertation work on how vascular 
remodeling affects dLN transport. Spontaneous development of adaptive immunity 
against melanomas is associated with improved clinical outcome [184], indicating the 
potential for melanoma immunotherapy. However, current immunotherapy results 
demonstrate limited efficacy due to the impaired surveillance of tumor antigen from 
rapidly mutating cancer cells and the influence of high concentrations of immune 
modulatory cytokines in the local immune milieu [185, 186]. Furthermore, normalizing 
the tumor’s vascular plexus may result in a more effective anti-tumor immune response 
by improving drainage of tumor antigens as well as cell-mediated transport to dLN and 
reducing the stagnant accumulation of immune modulatory cytokines within the tumor. 
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Characterizing changes in TSF heterogeneity, size distributions, and physical 
properties over the course of cancer progression and their potential effects on 
biodistribution profiles should be the focus of future studies. In ovarian cancer, exosomes 
from healthy ovarian epithelial cells were significantly larger than from malignant cell 
lines [187]. Additionally, the size distribution of exosomes changes with 
microenvironmental factors such as substrate stiffness and composition in an in vitro 
tumor model [188]. Potential changes in membrane thickness and the number of 
amphiphilic molecules incorporated in vesicle membranes may also influence the size 
distribution and, of equal importance given our current results, the stiffness of vesicles as 
indicated by energetic and thermodynamic models [189].  While our results herein 
provide a baseline understanding of molecular clearance and biodistribution from a 
primary melanoma, further studies on how the evolving physicochemical properties of 
TSF influence their transport is necessary to develop strategies to prevent their 
deleterious effects. 
6.2.2 Clinical Applications of Targeted Locoregional Immunotherapies 
As opposed to systemic immunotherapy, the benefits of locoregional therapies 
targeting the afflicted tissue of interest and the dLN are evident in higher local drug 
concentrations resulting in dose sparing and reduced off-target effects depending upon 
the engineered biomaterial platform used. Additionally, controlled release platforms 
administered in local tissues may provide more consistent drug exposure levels, reduce 
the need for repeated injections, and be cleared from the body less quickly than any 
platform introduced directly into circulation which will have to overcome first pass 
elimination by the reticuloendothelial system. Biomaterial-based locoregional 
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immunotherapy could be implemented in any disease case in which the diseased tissue 
and dLN are both desirable targets, such as the targeting of PD-L1 expressed by cancer 
cells in the tumor as well as antigen presenting cells in the TDLN using monoclonal 
antibody therapy. Further examples include intralymphatic immunotherapy [95, 96], 
allergic contact dermatitis, plaque psoriasis [97], and oncolytic virus therapy [98].  
6.2.3 Evaluation of Soluble Factor Transport in Other Inflammatory Diseases   
Future studies of chronic inflammatory diseases and wound healing applications 
that involve vascular remodeling may benefit from similar studies of soluble factor 
dissemination to reveal aberrant signaling pathways. Alternatively, accumulation of 
systemically-derived soluble factors could be enhanced by local vascular remodeling 
resulting in disease progression. Observations indicate patients with active rheumatoid 
arthritis exhibit circulating microparticles (0.2-1 µm in diameter, derived from platelets) 
at levels four to six times higher than healthy patients [190]. Interestingly, CD41+ 
platelet-derived microparticles, but not platelets themselves, were recently shown to 
present in the synovial fluid of patients with rheumatoid arthritis [191]. Surprisingly, such 
microparticles were not observed in the synovial fluid of osteoarthritis patients [191]. 
These microparticles were also shown to bind directly to leukocytes in the synovial fluid 
and play a role in amplifying the pathophysiology of rheumatoid arthritis, although the 
process by which these microparticles accumulate in the synovial fluid remains unknown. 
Investigating the role of SF in disease progression in other diseases which involve 
chronic inflammatory signaling and vascular remodeling may be worthwhile, including 
chronic inflammatory periodontal disease, asthma and chronic obstructive pulmonary 
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disease (COPD), pulmonary hypertension, certain cardiovascular diseases, Crohn’s 
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